<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Brain</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Brain</journal-id>
<journal-title-group>
<journal-title>Molecular Brain</journal-title>
</journal-title-group>
<issn pub-type="epub">1756-6606</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31752929</article-id>
<article-id pub-id-type="pmc">6873535</article-id>
<article-id pub-id-type="publisher-id">517</article-id>
<article-id pub-id-type="doi">10.1186/s13041-019-0517-5</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The impact of RASopathy-associated mutations on CNS development in mice and humans</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kang</surname>
<given-names>Minkyung</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6217-9574</contrib-id>
<name>
<surname>Lee</surname>
<given-names>Yong-Seok</given-names>
</name>
<address>
<phone>82-2-740-8225</phone>
<email>yongseok7@snu.ac.kr</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution>Department of Physiology, </institution><institution>Seoul National University College of Medicine, </institution></institution-wrap>103 Daehak-ro, Jongro-gu, Seoul, 03080 South Korea </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution>Department of Biomedical Sciences, </institution><institution>Seoul National University College of Medicine, </institution></institution-wrap>Seoul, 03080 Korea </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution>Neuroscience Research Institute, </institution><institution>Seoul National University College of Medicine, </institution></institution-wrap>103 Daehak-ro, Jongro-gu, Seoul, 03080 South Korea </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>21</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>21</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>12</volume>
<elocation-id>96</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">The RAS signaling pathway is involved in the regulation of developmental processes, including cell growth, proliferation, and differentiation, in the central nervous system (CNS). Germline mutations in the RAS signaling pathway genes are associated with a group of neurodevelopmental disorders, collectively called RASopathy, which includes neurofibromatosis type 1, Noonan syndrome, cardio-facio-cutaneous syndrome, and Costello syndrome. Most mutations associated with RASopathies increase the activity of the RAS-ERK signaling pathway, and therefore, most individuals with RASopathies share common phenotypes, such as a short stature, heart defects, facial abnormalities, and cognitive impairments, which are often accompanied by abnormal CNS development. Recent studies using mouse models of RASopathies demonstrated that particular mutations associated with each disorder disrupt CNS development in a mutation-specific manner. Here, we reviewed the recent literatures that investigated the developmental role of RASopathy-associated mutations using mutant mice, which provided insights into the specific contribution of RAS-ERK signaling molecules to CNS development and the subsequent impact on cognitive function in adult mice.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>RAS</kwd>
<kwd>MAPK</kwd>
<kwd>neurodevelopmental disorders</kwd>
<kwd>cognition</kwd>
<kwd>mutant strains mouse</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>National Research Foundation, Korea</institution>
</funding-source>
<award-id>NRF-2019R1A2C1084232</award-id>
<award-id>NRF-2019R1A4A2001609</award-id>
<award-id>NRF-2017M3C7A1026959</award-id>
<award-id>NRF-2016H1A2A1907206</award-id>
<principal-award-recipient>
<name>
<surname>Kang</surname>
<given-names>Minkyung</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Yong-Seok</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par31">The RAS-extracellular signal-regulated kinase (ERK) pathway is a highly conserved signaling cascade that transduces signals from membrane receptors to the cytoplasm and nucleus by protein–protein interactions and phosphorylation [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>]. It plays a critical role in controlling various cellular processes, including cell growth, survival, proliferation, and differentiation, in developing and adult tissues, such as the brain [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. <italic>RAS,</italic> which is composed of a multigene family that includes <italic>HRAS</italic>, <italic>KRAS</italic>, and <italic>NRAS,</italic> encodes a small guanosine nucleotide-bound GTPase protein, and the activation of the RAS-ERK signal transduction is initiated by the binding of growth factors to G-protein-coupled receptors, such as receptor tyrosine kinases (RTKs) and cytokine receptors. <italic>RAS</italic> is activated by guanine nucleotide exchange factors (GEFs), such as SOS1, whose activity is regulated by multiple adaptor proteins, including GAB1 and GRB2 (Fig. <xref ref-type="fig" rid="Fig1">1</xref>) [<xref ref-type="bibr" rid="CR5">5</xref>]. On the contrary, GTPase activating proteins (GAPs), such as NF1, switch RAS activity off by hydrolyzing GTP to GDP. The GTP-bound form of active RAS leads to the activation of its direct downstream effector, RAF. <italic>RAF</italic> encodes a serine/threonine kinase and represents the RAF family, which also includes ARAF, BRAF, and RAF1. RAF phosphorylates and activates the MAPK kinase, MAPK/ERK kinase 1/2 (MEK1/2), which in turn activates ERK1 and ERK2 by phosphorylating the tyrosine and threonine residues on ERK1/2 [<xref ref-type="bibr" rid="CR6">6</xref>]. ERK1 and ERK2 are homologous subtypes of the ERK family and are final effectors of the RAS-ERK pathway. ERK1/2 affect a large number of downstream molecules, such as nuclear components, transcription factors, and membrane proteins [<xref ref-type="bibr" rid="CR7">7</xref>].
<fig id="Fig1"><label>Fig. 1</label><caption><p>The RAS-ERK signaling pathway and associated disorders. A simplified RAS-ERK signaling pathway. Genes frequently mutated in RASopathy are colored based on the RASopathy and are displayed as a polygon depending on their functional categories. NS/NSML, Noonan syndrome/Noonan syndrome with multiple lentigines; NF1, Neurofibromatosis type 1; CS, Costello syndrome; CFCS, Cardio-facio-cutaneous syndrome; GEF, guanine exchange factor; GAP, GTPase activating protein.</p></caption><graphic id="MO1" xlink:href="13041_2019_517_Fig1_HTML"></graphic></fig></p>
<p id="Par32">Since the RAS-ERK pathway is critically involved in multiple biological processes, germline mutations in RAS-ERK signaling components can cause a class of developmental disorders that are collectively called RASopathy [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. RASopathy affects approximately 1 in 1,000 live births worldwide and shares a common molecular mechanism, such as mutations in RAS-ERK signaling components [<xref ref-type="bibr" rid="CR4">4</xref>]. Representatively, RASopathy includes 1) neurofibromatosis type 1, which is caused by loss of function mutations in <italic>NF1</italic>; 2) Noonan syndrome, caused by gain of function mutations in <italic>PTPN11</italic>, <italic>SOS1</italic>, <italic>SHOC2</italic>, <italic>CBL</italic>, <italic>KRAS</italic>, <italic>NRAS</italic>, <italic>BRAF</italic>, <italic>RAF1</italic>, and <italic>MEK1</italic>; 3) Noonan syndrome with multiple lentigines that is caused by mutations in <italic>PTPN11</italic> and <italic>RAF1</italic>; 4) cardio-facio-cutaneous syndrome, which is caused by either gain of function or loss of function mutations in <italic>BRAF</italic>, <italic>KRAS</italic>, <italic>MEK1</italic>, and <italic>MEK2</italic>; 5) Costello syndrome, caused by gain of function mutations in <italic>HRAS</italic>; and 6) neurofibromatosis type 1-like syndrome (NFLS or Legius syndrome) that is also caused by loss of function mutations in <italic>NF1</italic>. RASopathies share typical characteristics, such as a short stature, craniofacial dysmorphism, cardiac defects, and neurocognitive impairments that are accompanied by abnormal brain development [<xref ref-type="bibr" rid="CR10">10</xref>]. However, each RASopathy also displays distinct and unique symptoms, depending on the mutated genes [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Consistently, recent studies using mouse models of RASopathies have demonstrated that each disorder also shows disease-specific abnormalities in central nervous system (CNS) development. Here, we review the distinctive roles of RAS-ERK signaling molecules in CNS development that were revealed by investigating the deficits in CNS development of RASopathies (Tables <xref ref-type="table" rid="Tab1">1</xref> and <xref ref-type="table" rid="Tab2">2</xref>). Furthermore, we also review how RASopathy-associated mutations affect cognitive function in mice and human.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Human patients with RASopathies and their phenotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Disease</th><th>Associated genes</th><th>CNS structural phenotypes</th><th>Other phenotypes</th></tr></thead><tbody><tr><td>Neurofibromatosis type 1</td><td><italic>NF1</italic> (95%) [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td>Neurofibromas , abnormal cortical development [<xref ref-type="bibr" rid="CR13">13</xref>], abnormal glial development [<xref ref-type="bibr" rid="CR14">14</xref>], macrocephaly</td><td>Below-average IQ, ADHD, impaired executive functioning, deficits in visual-spatial skills [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], hyperpigmentation of melanocytes, hamartomas of the iris [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], bone malformation, cardiac defects [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr><td>Noonan syndrome, Noonan syndrome with multiple lentigines</td><td><italic>PTPN11</italic> (&gt;50%) [<xref ref-type="bibr" rid="CR21">21</xref>]<italic>, RAF1</italic> (3-17%) [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]<italic>, SOS1</italic> (9-13%) [<xref ref-type="bibr" rid="CR24">24</xref>] <italic>KRAS</italic> (&lt;2%) [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], <italic>BRAF</italic> (&lt;2%) [<xref ref-type="bibr" rid="CR22">22</xref>], <italic>MEK1/2</italic> (&lt;2%) [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>Cerebellar ectopia [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], temporal lobe anomaly, hydrocephalus, cerebral abscess [<xref ref-type="bibr" rid="CR30">30</xref>–<xref ref-type="bibr" rid="CR32">32</xref>], epilepsy, cortical dysplasia [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td>Neurocognitive delay [<xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR35">35</xref>], typical facial abnormalities, short stature, motor delay, increased risk of cancer, cardiac defects [<xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR40">40</xref>]</td></tr><tr><td>Cardio-facio-cutaneous syndrome</td><td><italic>BRAF</italic> (43-78%) [<xref ref-type="bibr" rid="CR41">41</xref>–<xref ref-type="bibr" rid="CR43">43</xref>], <italic>MEK</italic>1/2 (7-11%) [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>], <italic>KRAS</italic> (5-8%) [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]</td><td>Ventriculomegaly, hydrocephalus [<xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR50">50</xref>], atrophy [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR51">51</xref>–<xref ref-type="bibr" rid="CR54">54</xref>], migration and myelination abnormalities, agenesis of corpus callosum [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR55">55</xref>–<xref ref-type="bibr" rid="CR57">57</xref>]</td><td>Neurological abnormalities, seizures, tactile defensiveness, learning disabilities [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR55">55</xref>], craniofacial defects, cardiac defects [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>], motor delay, hypotonia [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td>Costello syndrome</td><td><italic>HRAS (85-90%)</italic> [<xref ref-type="bibr" rid="CR60">60</xref>–<xref ref-type="bibr" rid="CR62">62</xref>], <italic>KRAS</italic> (7%) [<xref ref-type="bibr" rid="CR63">63</xref>], <italic>BRAF</italic> (4-6%) [<xref ref-type="bibr" rid="CR27">27</xref>], <italic>MEK</italic>1/2 (2-3%) [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td>Ventricular abnormalities [<xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR67">67</xref>], cerebral malformations [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR67">67</xref>–<xref ref-type="bibr" rid="CR71">71</xref>], cerebellar abnormalities [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR71">71</xref>–<xref ref-type="bibr" rid="CR74">74</xref>], macrocephaly [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]</td><td>Mental retardation [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>], facial features, loose skin, severe failure to thrive, predisposition to tumors [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>IQ</italic> Intelligence quotient, <italic>ADHD</italic> Attention deficit hyperactivity disorder;</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>RASopathy mouse models and their phenotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Mouse model</th><th>CNS structural phenotypes</th><th>Other phenotypes</th></tr></thead><tbody><tr><td rowspan="6"><italic>Nf1</italic></td><td><italic>Nf1</italic> homozygous knockout</td><td>Defects in the neural tube, hyperplasia of neural crest-derived ganglia [<xref ref-type="bibr" rid="CR75">75</xref>]</td><td>Embryonic lethality, heart defects, delay in organ development [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]</td></tr><tr><td><italic>Nf1</italic> heterozygous knockout</td><td>Increased number of astrocytes [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]</td><td>Impaired synaptic plasticity, impaired spatial learning, heart defects [<xref ref-type="bibr" rid="CR80">80</xref>–<xref ref-type="bibr" rid="CR82">82</xref>]</td></tr><tr><td>Synapsin 1-dependent <italic>Nf1</italic> ablation</td><td>Reduced size and weight of the forebrain, reduced cortical thickness, increased astrogliogenesis [<xref ref-type="bibr" rid="CR83">83</xref>]</td><td>Learning deficits, growth retardation [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]</td></tr><tr><td>hGFAP-dependent <italic>Nf1</italic> ablation</td><td><p>Increased gliogenesis, enlarged cerebral cortex, defective GNP migration and proliferation</p><p>[<xref ref-type="bibr" rid="CR85">85</xref>–<xref ref-type="bibr" rid="CR88">88</xref>]</p></td><td>Postnatal lethality, growth retardation [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]</td></tr><tr><td>BLBP-dependent <italic>Nf1</italic> ablation</td><td>Increased glial lineage proliferation, abnormal neuronal differentiation [<xref ref-type="bibr" rid="CR89">89</xref>]</td><td>Postnatal lethality [<xref ref-type="bibr" rid="CR89">89</xref>]</td></tr><tr><td>Nestin-dependent <italic>Nf1</italic> ablation (induction in adulthood)</td><td>Unlocked latent oligodendrocyte lineage, defective GNP proliferation and migration, increased adult hippocampal neurogenesis [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR91">91</xref>]</td><td>Spontaneous antidepressive-like behavior [<xref ref-type="bibr" rid="CR91">91</xref>]</td></tr><tr><td rowspan="6"><italic>Ptpn11</italic></td><td>Nestin-dependent <italic>Ptpn11</italic> ablation</td><td>Decreased neural stem cell proliferation, lamination defects, reduced number of neurons, increased number of astrocytes [<xref ref-type="bibr" rid="CR92">92</xref>]</td><td>Postnatal lethality, growth retardation [<xref ref-type="bibr" rid="CR92">92</xref>]</td></tr><tr><td>Olig1-dependent <italic>Ptpn11</italic> ablation</td><td>Decreased number of oligodendrocyte precursors and mature oligodendrocytes, reduced axonal myelination [<xref ref-type="bibr" rid="CR93">93</xref>]</td><td>Developmental abnormalities [<xref ref-type="bibr" rid="CR93">93</xref>]</td></tr><tr><td>Olig2-dependent <italic>Ptpn11</italic> ablation</td><td>Decreased number of oligodendrocyte precursors, hypomyelination [<xref ref-type="bibr" rid="CR94">94</xref>]</td><td>Postnatal lethality, severe shivering [<xref ref-type="bibr" rid="CR94">94</xref>]</td></tr><tr><td>Olig2-dependent <italic>Ptpn11</italic><sup>Q79R</sup> knock-in</td><td>Increased number of oligodendrocyte precursors, abnormal myelination [<xref ref-type="bibr" rid="CR94">94</xref>]</td><td>Not described</td></tr><tr><td>Nestin-dependent <italic>Ptpn11</italic><sup>E76K</sup> knock-in</td><td>Hydrocephalus, aberrant development of ependymal cells, reduced proliferation, enhanced glial differentiation [<xref ref-type="bibr" rid="CR95">95</xref>]</td><td>Postnatal lethality, dome-shaped head, reduced anxiety behavior, hyperactivity, impaired motor function [<xref ref-type="bibr" rid="CR95">95</xref>]</td></tr><tr><td><italic>Ptpn11</italic><sup>D61G</sup> herozygous knock-in</td><td>Increased neurogenesis, decreased gliogenesis [<xref ref-type="bibr" rid="CR96">96</xref>]</td><td>Impaired synaptic plasticity, impaired spatial learning, short stature, craniofacial dysmorphia [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]</td></tr><tr><td><italic>Kras</italic></td><td>Synapsin1-dependent <italic>Kras</italic><sup>G12V</sup> knock-in</td><td>Enhanced GABAergic synaptogenesis [<xref ref-type="bibr" rid="CR99">99</xref>]</td><td>Increased inhibitory tone, impaired spatial learning [<xref ref-type="bibr" rid="CR99">99</xref>]</td></tr><tr><td rowspan="2"><italic>Hras</italic></td><td><italic>Hras</italic><sup>G12V</sup> homozygous knock-in</td><td>Hypertrophy of the brain and pyramidal neurons [<xref ref-type="bibr" rid="CR100">100</xref>]</td><td>Impaired spatial learning, facial dysmorphia, cardiac defects [<xref ref-type="bibr" rid="CR100">100</xref>]</td></tr><tr><td>aCaMKII-dependent <italic>Hras</italic><sup>G12V</sup> knock-in</td><td>Increase in docked vesicles [<xref ref-type="bibr" rid="CR101">101</xref>]</td><td>Increased synaptic plasticity, enhanced spatial learning [<xref ref-type="bibr" rid="CR101">101</xref>]</td></tr><tr><td rowspan="2"><italic>Braf</italic></td><td>Nestin-dependent <italic>Braf</italic> ablation</td><td>Impaired neuronal differentiation, dysmyelination, defective oligodendrocyte differentiation [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]</td><td>Postnatal lethality, growth retardation, defective motor coordination, neuromuscular defects [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]</td></tr><tr><td><italic>Braf</italic><sup>V600E</sup> heterozygous knock-in</td><td>Increased number of GFAP positive cells in the DG [<xref ref-type="bibr" rid="CR104">104</xref>]</td><td>Reduced life span, growth retardation, facial dysmorphia, cardiomegaly, epileptic seizures [<xref ref-type="bibr" rid="CR104">104</xref>]</td></tr><tr><td rowspan="2"><italic>Raf1</italic></td><td><italic>Raf1</italic> heterozygous knockout</td><td>Small granule cell volume, increased cell death, reduced neuronal maturation [<xref ref-type="bibr" rid="CR105">105</xref>]</td><td>Postnatal lethality, growth retardation, apoptosis in the lung and liver, limbs coordination problems [<xref ref-type="bibr" rid="CR106">106</xref>]</td></tr><tr><td><italic>Raf1</italic><sup>L613V</sup> heterozygous knock-in</td><td>Increased density of astrocytes, enhanced OPCs density [<xref ref-type="bibr" rid="CR107">107</xref>]</td><td>Enhanced learning and memory [<xref ref-type="bibr" rid="CR107">107</xref>]</td></tr><tr><td rowspan="4"><italic>Mek1/2</italic></td><td><italic>Mek1</italic><sup>Y130C</sup> homozygous knock-in</td><td>Increased astrocyte density, increased number of cortical oligodendrocytes [<xref ref-type="bibr" rid="CR108">108</xref>]</td><td>Pulmonary artery stenosis, cranial dysmorphia [<xref ref-type="bibr" rid="CR108">108</xref>]</td></tr><tr><td>Nestin-dependent <italic>Mek1/2</italic> ablation</td><td>Decrease of astrocyte precursors and OPCs, failure of gliogenesis [<xref ref-type="bibr" rid="CR109">109</xref>]</td><td>Early postnatal lethality [<xref ref-type="bibr" rid="CR109">109</xref>]</td></tr><tr><td>hGFAP-dependent <italic>Mek1/2</italic> ablation</td><td>Suppressed generation of astrocyte precursors and OPCs, failure of gliogenesis [<xref ref-type="bibr" rid="CR109">109</xref>]</td><td>Postnatal lethality [<xref ref-type="bibr" rid="CR109">109</xref>]</td></tr><tr><td>hGFAP-dependent <italic>Mek1</italic><sup>S218E,S222E</sup></td><td>Increase in astrocyte precursors and mature astrocytes, reduction of neuron number [<xref ref-type="bibr" rid="CR109">109</xref>]</td><td>Not described</td></tr></tbody></table><table-wrap-foot><p><italic>hGFAP</italic> Human glial fibrillary acidic protein, <italic>BLBP</italic> Brain lipid binding protein, <italic>GNP</italic> Granule neuron progenitor, <italic>DG</italic> Dentate gyrus, <italic>OPCs</italic> Oligodendrocyte progenitor cells</p></table-wrap-foot></table-wrap></p>
<sec id="Sec2">
<title>RAS-ERK signaling and nervous system development</title>
<p id="Par33">The RAS-ERK signaling pathway is tightly regulated during CNS development and many studies have demonstrated that the dysregulation of this signaling pathway results in aberrant brain development. There are a number of studies demonstrating that ERK1/2, the final effectors of RAS-ERK signaling, are involved in cell proliferation and differentiation in the nervous system [<xref ref-type="bibr" rid="CR110">110</xref>]. Activation of ERK signaling is required for neural stem cells (NSCs) to maintain their ability to self-renew and form neurospheres, indicating that ERK may act as a critical regulator in the maintenance of NSCs [<xref ref-type="bibr" rid="CR111">111</xref>]. In addition, it has also been shown that ERK signaling promotes neuronal survival by multiple mechanisms [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. For example, an ERK-activated kinase, ribosomal S6 Kinase (RSK), phosphorylates the pro-apoptotic protein BAD and suppresses BAD-mediated apoptosis in neurons [<xref ref-type="bibr" rid="CR112">112</xref>]. ERK was also shown to regulate the activation of anti-apoptotic regulators, such as Bcl-2, CREB, and STAT3/5, and subsequently promote cell survival [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. However, in spite of the crucial role of ERK in neuronal survival, aberrant and long-lasting ERK activation has also been implicated in neurodegenerative diseases [<xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR117">117</xref>].</p>
<p id="Par34">Several studies have implied that the MEK/ERK signaling cascade has a crucial role in neurogenesis. ERK2 is necessary for regulating the proliferation of neurogenic precursors and the positive regulation of neurotrophin-induced neurogenesis by the MEK-C/EBP pathway during cortical development [<xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR119">119</xref>]. Despite the evidence that MEK is required for neurogenesis, in vivo and in vitro studies have demonstrated that ERK also regulates and maintains the pool of glial populations in the developing brain [<xref ref-type="bibr" rid="CR109">109</xref>]. NSC-specific ablation of <italic>Mek1/2</italic> induces a complete blockade of glial specificity and gliogenesis failure, while <italic>Mek1</italic> gain of function promotes precocious glial progenitor specification in mice [<xref ref-type="bibr" rid="CR109">109</xref>]. <italic>S</italic>everal studies have demonstrated that in vitro, <italic>Erk1</italic> and <italic>Erk2</italic> are critical components of proliferation in cultured rat astrocytes, and that MEK/ERK signaling induces gliogenic signals, such as SDF-1a and FGF2 [<xref ref-type="bibr" rid="CR120">120</xref>–<xref ref-type="bibr" rid="CR122">122</xref>]. Consistently, treatment with the MEK inhibitor PD98059 induced a reduction in astrocytic growth, suggesting that MEK/ERK signaling is involved in astrocyte proliferation [<xref ref-type="bibr" rid="CR122">122</xref>]. In addition, the chemical inhibition of MEK also impairs the ability of oligodendrocyte precursors to differentiate into mature oligodendrocyte in vitro, suggesting that both oligodendrocytes and astrocytes are regulated by ERK signaling [<xref ref-type="bibr" rid="CR103">103</xref>]. Several studies demonstrated that the pharmacological inhibition of ERK1/2 signaling in oligodendrocyte progenitors negatively regulates differentiation and the transition of early progenitors to late oligodendrocyte progenitors [<xref ref-type="bibr" rid="CR123">123</xref>–<xref ref-type="bibr" rid="CR125">125</xref>]. Furthermore, ERK signaling promotes oligodendrocyte myelination [<xref ref-type="bibr" rid="CR126">126</xref>]. However, there are conflicting results about the role of ERK signaling in the differentiation of oligodendrocyte progenitors into mature oligodendrocytes. Recently, Suo and colleagues demonstrated that MEK inhibitors significantly enhance the differentiation of oligodendrocyte precursor cells into oligodendrocytes in vitro and in vivo [<xref ref-type="bibr" rid="CR127">127</xref>]. Consistently, many studies have suggested that increased ERK activity negatively regulates oligodendrocyte differentiation. For example, ERK1/2 activation, which is induced by high dose stimulation of neuregulin-1 or fibroblast growth factor-2 in mature oligodendrocytes, results in downregulated myelin proteins and aberrant cell cycle re-entry [<xref ref-type="bibr" rid="CR128">128</xref>–<xref ref-type="bibr" rid="CR130">130</xref>].</p>
<p id="Par35">The RAS-ERK signaling pathway also regulates the expression of transcription factors, such as cell fate determinants. Numerous studies demonstrated that the enhanced activity of RAS-ERK signaling induces the expression of the transcription factor <italic>OLIG2,</italic> which promotes the fate of NSCs to the glial lineage [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. Furthermore, the activation of RAS-ERK signaling promotes the expression of the pro-neural gene <italic>Achaete scute-like 1</italic> (<italic>Ascl1</italic>) but blocks pro-neural gene <italic>Neurogenin 2</italic> (<italic>Neurog2</italic>) expression. <italic>Neurog2</italic> specifies glutamatergic neuronal cell fate in dorsal progenitors, while <italic>Ascl1</italic> specifies neocortical gamma-aminobutyric acidergic (GABAergic) neurons and oligodendrocyte precursor cells [<xref ref-type="bibr" rid="CR131">131</xref>–<xref ref-type="bibr" rid="CR133">133</xref>]. Therefore, during normal early developmental stages, RAS-ERK signaling activity is kept low so that <italic>Neurog2</italic> is able to promote glutamatergic neuronal differentiation of embryonic cortical progenitors. However, in an abnormal context where the RAS-ERK signaling is elevated, <italic>Neurog2</italic> expression is switched to <italic>Ascl1</italic> expression [<xref ref-type="bibr" rid="CR134">134</xref>]. During moderate activation of RAS-ERK signaling, <italic>Ascl1</italic> expression promotes GABAergic neuronal differentiation, while <italic>Ascl1</italic> promotes proliferative glioblast phenotypes when RAS-ERK signaling is highly active [<xref ref-type="bibr" rid="CR134">134</xref>].</p>
<p id="Par36">RAS interacts with and regulates other signaling pathways in addition to the MEK/ERK cascade. As one of the main effector pathways of RAS, the phosphatidylinositol 3-kinase (PI3K)-AKT pathway regulates protein synthesis and variety of cellular processes such as cell growth, cycle entry, and cellular survival [<xref ref-type="bibr" rid="CR135">135</xref>–<xref ref-type="bibr" rid="CR137">137</xref>]. The Ras and PI3K-AKT pathway were shown to activate and inhibit each other via multiple cross-talks [<xref ref-type="bibr" rid="CR138">138</xref>]. Studies using rodent models have reported distinct phenotypes and revealed a pivotal role of PI3K signaling in nervous systems. For instance, deleting a PI3K isoform PI3Kγ in mice impaired synaptic plasticity and behavioral flexibility, while its overexpression through viral vector resulted in impaired synaptic plasticity and spatial learning [<xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR140">140</xref>]. The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is also a well characterized cascade known to interact with RAS-ERK [<xref ref-type="bibr" rid="CR141">141</xref>]. JAK activation stimulates cell proliferation, differentiation, cell migration and apoptosis, and there are compelling evidences that JAK-STAT pathway plays essential roles in synaptic plasticity [<xref ref-type="bibr" rid="CR142">142</xref>].</p>
</sec>
<sec id="Sec3">
<title>RASopathies and central nervous system development</title>
<sec id="Sec4">
<title>Neurofibromatosis type 1</title>
<p id="Par37">Neurofibromatosis type 1 (NF1) is a relatively common developmental disease that affects 1 in 3,000 individuals and is diagnosed by both somatic and behavioral symptoms [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR143">143</xref>]. NF1 is caused by loss of function mutations in <italic>NF1</italic> alleles [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]. The <italic>NF1</italic> gene encodes a GAP for RAS, neurofibromin, which promotes the conversion of active RAS-GTP to inactive RAS-GDP, thus, negatively regulating the RAS-ERK signaling pathway [<xref ref-type="bibr" rid="CR145">145</xref>, <xref ref-type="bibr" rid="CR146">146</xref>]. Therefore, loss of function mutations in <italic>NF1</italic> result in the hyperactivation of RAS-ERK signaling. As mutations in the <italic>NF1</italic> gene lead to abnormal cell growth, proliferation, and differentiation, individuals with NF1 frequently display neurofibromas, hyperpigmentation of melanocytes, and hamartomas of the iris [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Additionally, common features of NF1 include bone malformations, cardiac defects, and neurocognitive impairments [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. More than 75% of NF1 patients suffer from cognitive deficits, such as below-average IQ and specific deficits in attention, executive functioning, and visual-spatial skills [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p>
<p id="Par38">Although tumor development in the peripheral nervous system is a hallmark of NF1, a variety of CNS abnormalities, including neurofibroma, have been reported in NF1 patients [<xref ref-type="bibr" rid="CR147">147</xref>]. For example, abnormal cortical lamination and a compressed cerebral cortex were observed in the brains of NF1 patients, indicating a critical role for <italic>NF1</italic> in cortical development [<xref ref-type="bibr" rid="CR13">13</xref>]. Interestingly, several studies have also suggested that NF1 is associated with deficits in glial development. For example, children with NF1 display abnormalities in astrocyte growth regulation and tend to develop astrocytoma [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR148">148</xref>]. Similarly, a postmortem study reported that three NF1 brains exhibited extensively increased astrogliogenesis [<xref ref-type="bibr" rid="CR149">149</xref>]. Specifically, an association between an enlarged corpus callosum and severe learning disabilities in a subpopulation of NF1 patients has been reported [<xref ref-type="bibr" rid="CR150">150</xref>, <xref ref-type="bibr" rid="CR151">151</xref>]. Moore and colleagues also reported that the total brain volume, especially the gray matter, was significantly larger in NF1 subjects than in children and adolescents without NF1. The gray matter volume in NF1 subjects was inversely correlated with their degree of learning disability [<xref ref-type="bibr" rid="CR150">150</xref>]. Taken together, individuals with NF1 display CNS developmental abnormalities, including promoted astrogliogenesis and structural malformation, which might be associated with learning disabilities.</p>
<p id="Par39"><italic>Nf1</italic> homozygous knockout mice (<italic>Nf1</italic><sup>-/-</sup>) die <italic>in utero</italic> because of severe heart malformations, a delay in renal, hepatic, and skeletal muscle development, and hyperplasia of neural crest-derived sympathetic ganglia [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. In addition, <italic>Nf1</italic>-deficient mouse embryos exhibit defects in the neural tube, including exencephaly or the thinning of the dorsal telencephalic wall, although the targeted allele in this study was slightly different from previous investigations [<xref ref-type="bibr" rid="CR75">75</xref>]. Therefore, a heterozygous knockout mouse line (<italic>Nf1</italic><sup>+/-</sup>) has been extensively used to investigate the cellular mechanisms underlying NF1 etiology [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>]. Silva and colleagues showed that <italic>Nf1</italic><sup>+/-</sup> mice display impaired spatial learning and impaired hippocampal synaptic plasticity [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. Mechanisms underlying the deficits in learning and synaptic plasticity in NF1 mouse models have been extensively reviewed in previous publications [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR154">154</xref>]. In line with human patients, <italic>Nf1</italic> heterozygous mutant mice showed developmental abnormalities in the heart and neural crest-derived tissues, and an increased number of astrocytes with high levels of glial fibrillary acidic protein (GFAP) in the periaqueductal grey, nucleus accumbens, and hippocampus [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR79">79</xref>].</p>
<p id="Par40">Ablation of <italic>Nf1</italic> only in neurons by using the Synapsin I promoter (<italic>Nf1</italic><sup>Syn1</sup>) led to growth retardation, including reduced body weight and size, that was sustained into adulthood [<xref ref-type="bibr" rid="CR83">83</xref>]. <italic>Nf1</italic><sup>Syn1</sup> conditional knockout (CKO) mice exhibited reduced size and weight of the forebrain, but not other brain regions [<xref ref-type="bibr" rid="CR83">83</xref>]. Histological analyses of CKO mice also revealed remarkable defects in the cerebral cortex, such as a reduction in cortical thickness [<xref ref-type="bibr" rid="CR83">83</xref>]. Neuronal loss in mutant cortices was not detected; however, interestingly, CKO mice displayed extensive GFAP immunoreactivity throughout the cerebral cortex, hippocampus, and brainstem, which indicates increased astrogliogenesis [<xref ref-type="bibr" rid="CR83">83</xref>]. These results indicate that <italic>Nf1</italic> has an indispensable role in CNS development, and that <italic>Nf1</italic>-deficient neurons induce astroglial hypertrophy and GFAP induction through a paracrine effect [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR155">155</xref>].</p>
<p id="Par41">Several studies suggested that neurofibromin might be required for NSCs or neuroglial progenitor function, and that <italic>Nf1</italic> mutations affect both astroglial and neuronal lineages. Studies using a well-characterized human GFAP (hGFAP)-Cre transgenic mouse line have demonstrated that <italic>Nf1</italic> plays a critical role in CNS development. Typically, hGFAP-Cre expression is first detected in radial glia, which give rise to both neuronal and glial lineage cells, around embryonic day 13 [<xref ref-type="bibr" rid="CR156">156</xref>]. Mutant <italic>Nf1</italic><sup>hGFAP</sup> CKO mice, which lack neurofibromin in the majority of their cortical neurons and astrocytes, were born in normal numbers, but became noticeably smaller than their littermates over time, and typically died by four months of age [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. <italic>Nf1</italic><sup>hGFAP</sup> CKO mice displayed enlarged cerebral cortices and an increased brain to body weight ratio caused by the enlarged cortex [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. The mutant mice also exhibited a notably smaller cerebellum, compared with littermates, and defective migration and proliferation of granule neuron progenitors [<xref ref-type="bibr" rid="CR88">88</xref>]. In addition, <italic>Nf1</italic><sup>hGFAP</sup> CKO mice failed to form cortical barrels in the somatosensory cortex, although segregation of thalamic axons within the somatosensory cortex was unaffected [<xref ref-type="bibr" rid="CR87">87</xref>]. Consistent with NF1 patients, the mutant mice displayed increased GFAP-positive astrocytes throughout both the gray and the white matter, including the corpus callosum and anterior commissure [<xref ref-type="bibr" rid="CR86">86</xref>]. Wang and colleagues also showed that the <italic>Nf1</italic><sup>hGFAP</sup> CKO mice display increased gliogenesis at the expense of neurogenesis in the neonatal period and during adulthood [<xref ref-type="bibr" rid="CR85">85</xref>]. Due to the altered ratio of glia to neurons, <italic>Nf1</italic><sup>hGFAP</sup> CKO mice displayed a smaller olfactory bulb and an enlarged corpus callosum, providing a link between brain structural abnormalities and cognitive impairments in animal models and those seen in NF1 patients [<xref ref-type="bibr" rid="CR85">85</xref>]. Similarly, <italic>Nf1</italic> inactivation in neuroglial progenitors using a brain lipid binding protein (BLBP)-Cre mouse strain also led to increased glial proliferation and abnormal neuronal differentiation in vivo [<xref ref-type="bibr" rid="CR89">89</xref>]. However, it is also noteworthy to mention that deleting <italic>Nf1</italic> using GFAP-Cre did not impair either learning or synaptic plasticity in adult mice [<xref ref-type="bibr" rid="CR84">84</xref>].</p>
<p id="Par42">Recent studies reported that <italic>Nf1</italic> regulates cell fate specificity and cellular processes in both the developmental stage and in adulthood. Inactivation of <italic>Nf1</italic> in adult NSCs unlocked a latent oligodendrocyte lineage and allowed NSCs to produce all three lineages in vivo [<xref ref-type="bibr" rid="CR90">90</xref>]. Similarly, postnatal <italic>Nf1</italic> ablation using Nestin-CreERT2 was sufficient to cause cerebellar abnormalities, including defective cerebellar foliation, granule neuron progenitors (GNPs) proliferation, and migration [<xref ref-type="bibr" rid="CR88">88</xref>]. Also, deletion of <italic>Nf1</italic> in adult hippocampal neural progenitor cells led to enhanced proliferation and an increase in new neurons in the dentate gyrus [<xref ref-type="bibr" rid="CR91">91</xref>].</p>
<p id="Par43">Since <italic>Nf1</italic> also functions as a tumor suppressor gene, in vitro studies in various cell types have suggested that <italic>Nf1</italic> mutations are associated with growth abnormalities, such as increased proliferation of oligodendrocyte precursors in the embryonic spinal cord [<xref ref-type="bibr" rid="CR157">157</xref>] and Schwann cells [<xref ref-type="bibr" rid="CR158">158</xref>]. Particularly, <italic>Nf1</italic><sup>-/-</sup> and <italic>Nf1</italic><sup>+/-</sup> NSCs generate increased numbers of morphologically abnormal, immature astroglial cells in vitro [<xref ref-type="bibr" rid="CR159">159</xref>]. The increase in astroglial progenitors and proliferating cells seen in vitro was also observed in <italic>Nf1</italic><sup>-/-</sup> and <italic>Nf1</italic><sup>+/-</sup> embryonic brains and <italic>Nf1</italic><sup>+/-</sup> adult brains in vivo [<xref ref-type="bibr" rid="CR159">159</xref>]. In addition, Lee and colleagues showed that <italic>Nf1</italic><sup>-/-</sup> NSCs from the brainstem exhibit increased proliferation and glial cell differentiation in vitro and in vivo; however, the lack of effect on neocortex NSCs proliferation or gliogenesis suggests that the effects of <italic>Nf1</italic> gene inactivation are brain region-specific [<xref ref-type="bibr" rid="CR160">160</xref>].</p>
<p id="Par44">What would be an underlying mechanism for the enhanced glial population in NF1? It has been demonstrated that <italic>Nf1</italic> inactivation in neural stem/progenitor cells can alter glia/neuron fate specification by promoting the expression of <italic>Olig2</italic>, a basic-helix-loop-helix transcription factor that is required for oligodendrocyte progenitor cell specification [<xref ref-type="bibr" rid="CR161">161</xref>]. <italic>Nf1</italic><sup>hGFAP</sup> CKO and <italic>Nf1</italic><sup>BLBP</sup> CKO mutant mice showed increased <italic>Olig2</italic> expression, suggesting that <italic>Nf1</italic> suppresses <italic>Olig2</italic> expression and the oligodendrocyte progenitor lineage in neonatal subventricular zone progenitor cells [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR160">160</xref>]. In concordance with the neonatal study, inactivation of <italic>Nf1</italic> in adult NSCs also resulted in increased <italic>Olig2</italic> expression [<xref ref-type="bibr" rid="CR90">90</xref>]. In conclusion, these studies with <italic>Nf1</italic> mutant mice revealed the essential role of NF1 in CNS development, including the gross morphology and proper formation of several brain region structures, and the regulation of cell fate.</p>
<p id="Par45">Along with structural abnormalities in CNS, several lines of evidence suggest that the distribution of <italic>NF1</italic> in single neuronal cell type may also contribute to cognitive deficits in NF1. Transcriptome analyses of mouse brain have unveiled the enriched <italic>NF1</italic> expression in inhibitory neurons rather than the in excitatory neurons, and provided a clue as to how <italic>NF1</italic> mainly carries out its role in inhibitory synaptic function [<xref ref-type="bibr" rid="CR162">162</xref>]. Furthermore, based on the conserved expression pattern of <italic>NF1</italic> in human brain, it is suggested that the enriched expression of <italic>NF1</italic> in inhibitory neurons may underlie cell type-specific pathophysiology and cognitive deficits in NF1 [<xref ref-type="bibr" rid="CR163">163</xref>].</p>
<p id="Par46"><italic>Nf1</italic> mutant mice mimic most of the CNS features found in NF1 human patients, including increased brain volume, enlarged corpus callosum and cortical area, and especially, enhanced gliogenesis, which may be closely associated with structural abnormalities. Despite compelling evidences of the expression of glial lineage transcription factors such as <italic>Olig2</italic> increasing as RAS-ERK highly activates [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR108">108</xref>], yet it is unclear how RAS-ERK pathway regulates cell fate determinants. Thus, for understanding CNS abnormalities in NF1 patients, it is worth investigating the expression regulations of cell fate determinants with regard to RAS-ERK activity.</p>
</sec>
<sec id="Sec5">
<title>Noonan syndrome and Noonan syndrome with multiple lentigines</title>
<p id="Par47">Noonan syndrome (NS) is an autosomal dominant genetic disorder with an incidence of 1 in 2,500 live births [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR165">165</xref>]. This complex disorder occurs both in familial and sporadic forms [<xref ref-type="bibr" rid="CR166">166</xref>]. Germline mutations in genes involved in RAS-ERK signaling pathway have been reported to be associated with NS, such as the gain of function mutations in <italic>protein tyrosine phosphatase non-receptor type 11</italic> (<italic>PTPN11</italic>), <italic>son of sevenless homolog 1</italic> (<italic>SOS1</italic>), <italic>Kirsten rat sarcoma viral oncogene homolog</italic> (<italic>KRAS</italic>), <italic>neuroblastoma RAS viral oncogene homolog</italic> (<italic>NRAS</italic>), <italic>Raf-1 proto-oncogene</italic> (<italic>RAF1</italic>), <italic>BRAF</italic>, <italic>soc-2 suppressor of clear homolog</italic> (<italic>SHOC2</italic>), and <italic>MEK1</italic>, and the loss of function mutations in <italic>Cbl proto-oncogene</italic> (<italic>CBL</italic>) [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]. Above all, mutations in <italic>PTPN11,</italic> which encodes the non-receptor protein phosphatase SHP2, account for approximately 50% of NS cases [<xref ref-type="bibr" rid="CR167">167</xref>]. Patients with NS are characterized by typical facial abnormalities, such as a broad forehead, sparse eyebrows, a low-set and posteriorly rotated ear, and a webbed neck, while other important features include a short stature, motor delay, increased risk of cancer, and cardiac defects [<xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR40">40</xref>]. Noonan syndrome with multiple lentigines (NSML) patients have most of the clinical symptoms observed in individuals with NS, but they also display increased penetrance of hypertrophic cardiomyopathy and lentigines [<xref ref-type="bibr" rid="CR168">168</xref>]. Distinct from NS, <italic>PTPN11</italic> loss of function mutations result in NSML [<xref ref-type="bibr" rid="CR168">168</xref>].</p>
<p id="Par48">Between 30%-50% of NS patients show a variable degree of neurocognitive delay, but there are relatively few reports of CNS malformations in NS individuals [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Two cases of NS were reported to be associated with cerebellar ectopia [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. In addition, there are several reports of NS being associated with a temporal lobe anomaly, hydrocephalus, cerebral abscess, and malignant Schwannoma [<xref ref-type="bibr" rid="CR30">30</xref>–<xref ref-type="bibr" rid="CR32">32</xref>]. In particular, Saito and colleagues reported one case of an NS patient with severe mental retardation and intractable epilepsy [<xref ref-type="bibr" rid="CR33">33</xref>]. The patient also displayed cortical dysplasia, including dilated perivascular spaces and a dysplastic lesion in the left temporal lobe [<xref ref-type="bibr" rid="CR33">33</xref>].</p>
<p id="Par49">Mutant mice harboring NS-associated <italic>Sos1</italic><sup>E846K</sup>, <italic>Kras</italic><sup>V14I</sup>, and <italic>Raf1</italic><sup>L613V</sup> displayed a short stature, facial dysmorphia, growth retardation, and cardiac defects, which are characteristic features of NS patients [<xref ref-type="bibr" rid="CR169">169</xref>–<xref ref-type="bibr" rid="CR172">172</xref>]. Since <italic>PTPN11</italic> mutations are the majority among NS cases, Shp2 mutant mice are one of the most studied models of NS [<xref ref-type="bibr" rid="CR96">96</xref>–<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR174">174</xref>]. A subpopulation of NS patients have a constitutively active mutation Shp2<sup>D61G</sup>, which has a highly increased phosphatase activity [<xref ref-type="bibr" rid="CR175">175</xref>, <xref ref-type="bibr" rid="CR176">176</xref>]. The homozygous Shp2<sup>D61G</sup> mutation was eventually embryonically lethal, as the embryos were grossly hemorrhagic and edematous, showed a decreased liver size, and had cardiac defects [<xref ref-type="bibr" rid="CR98">98</xref>]. However, half of heterozygous Shp2<sup>D61G</sup> mice that carried only one copy of the mutant allele (Shp2<sup>D61G/+</sup>) survived, and displayed a short stature and craniofacial dysmorphia, such as wide-set eyes, a broad forehead, and a triangular face, which were similar to NS patients [<xref ref-type="bibr" rid="CR98">98</xref>]. Heterozygous Shp2<sup>D61G</sup> mice also showed deficits in spatial learning and memory and had impaired synaptic plasticity [<xref ref-type="bibr" rid="CR97">97</xref>]. Mice carrying a milder mutation, Shp2<sup>N308D</sup>, displayed some cardiac defects and mild impairment to spatial learning and memory that was consistent with human cases [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Neural crest cell-specific Shp2<sup>Q79R</sup> resulted in craniofacial defects and growth retardation [<xref ref-type="bibr" rid="CR170">170</xref>]. Neural stem cell-specific expression of Shp2<sup>E76K</sup> by using Nestin-Cre resulted in hydrocephalus due to aberrant development of ependymal cells [<xref ref-type="bibr" rid="CR95">95</xref>]. In addition, Shp2<sup>E76K</sup>-expressing mice showed hyperactivity accompanied by reduced anxiety behavior, and impaired motor function [<xref ref-type="bibr" rid="CR95">95</xref>]. Global Shp2<sup>D61Y</sup> expression resulted in embryonic lethality, while epiblast-specific Shp2<sup>D61Y</sup> expression induced embryonic cardiac defects [<xref ref-type="bibr" rid="CR173">173</xref>].</p>
<p id="Par50">SHP2 is a growth factor-regulated phosphatase that modulates both the RAS-ERK and the gp130-JAK-STAT pathways [<xref ref-type="bibr" rid="CR177">177</xref>, <xref ref-type="bibr" rid="CR178">178</xref>]. Since both pathways are known to play critical roles in cell proliferation and differentiation, several studies demonstrated that SHP2 affects cell proliferation and differentiation in large range of cell types [<xref ref-type="bibr" rid="CR179">179</xref>–<xref ref-type="bibr" rid="CR183">183</xref>]. For example, SHP2 is required for the initiation of retinal neurogenesis and it regulates the patterning of optic vesicles by mediating retinal progenitor factors and cell proliferation [<xref ref-type="bibr" rid="CR184">184</xref>]. Huang and colleagues have shown that the suppression of SHP2 activity reduces cell migration and neurite outgrowth, and that it decreases the differentiation-induced activation of FAK, Src, paxillin, and ERK1/2 [<xref ref-type="bibr" rid="CR185">185</xref>]. Also, the authors demonstrated that SHP2 is recruited to focal adhesions in NSCs and that it regulates focal adhesion formation [<xref ref-type="bibr" rid="CR185">185</xref>].</p>
<p id="Par51">Recent studies have suggested that Shp2 is involved in oligodendrocyte development in the telencephalon. <italic>In vitro</italic> studies using rat cortical cultures demonstrated different roles for Shp2 in either oligodendrocyte precursor cell proliferation or maturation [<xref ref-type="bibr" rid="CR186">186</xref>, <xref ref-type="bibr" rid="CR187">187</xref>]. The in vivo function of Shp2 in oligodendrocyte differentiation was also investigated by Zhu and colleagues using conditional mutant mice with a selective Shp2 deletion in Olig1-expressing cells in the ventral spinal cord [<xref ref-type="bibr" rid="CR93">93</xref>]. The mutant mice displayed a dramatic reduction in the number of both oligodendrocyte precursor cells and mature oligodendrocytes and decreased axonal myelination in the developing CNS, suggesting that Shp2 is a critical regulator of oligodendrocyte proliferation and differentiation [<xref ref-type="bibr" rid="CR93">93</xref>]. Similarly, Ehrman and colleagues investigated the role of Shp2 in ventricular zone progenitor cells of the ventral telencephalon and in cells of the oligodendrocyte lineage by deleting Shp2 in <italic>Olig2</italic>-positive cells [<xref ref-type="bibr" rid="CR94">94</xref>]. Olig2-specific Shp2 null mutant mice showed a significant decrease in the number of oligodendrocyte progenitor cells, at embryonic and postnatal stages, and severe hypomyelination [<xref ref-type="bibr" rid="CR94">94</xref>]. Moreover, expressing an NS-associated mutation Shp2<sup>Q79R</sup> using Olig2-Cre increased the number of oligodendrocyte precursor cells in the embryonic and postnatal brain, but also induced abnormal myelination and fewer myelinated axons in the white matter [<xref ref-type="bibr" rid="CR94">94</xref>].</p>
<p id="Par52">SHP2 has been shown to play a role in cell fate decisions as it promotes neurogenesis and suppresses astrogliogenesis through the repression of the JAK-STAT pathway, which is required for astrocyte formation in the developing brain. Gauthier and colleagues reported that germline Shp2<sup>D61G</sup> heterozygous mice showed more neurons and fewer astrocytes in the hippocampus and dorsal cortex at postnatal day 2, and suggested that NS-associated mutations cause brain abnormalities by disrupting the balance of CNS populations [<xref ref-type="bibr" rid="CR96">96</xref>]. Ke and colleagues also demonstrated that SHP2 is an important player in mammalian brain development by generating a novel mutant mouse in which Shp2 is selectively eliminated in neural precursor cells [<xref ref-type="bibr" rid="CR92">92</xref>]. The mutant mouse showed early postnatal lethality, decreased proliferation of NSCs, and lamination defects in the developing cerebral cortex [<xref ref-type="bibr" rid="CR92">92</xref>]. Mutant mice showed a reduced number of neurons and an increased number of astrocytes, which imply defective neuronal differentiation and modestly enhanced astrogliogenesis, supporting the idea that Shp2 promotes neurogenesis and suppresses astrocytogenesis [<xref ref-type="bibr" rid="CR92">92</xref>]. The peripheral nervous system of Wnt1-Cre or Krox20-Cre conditional Shp2 floxed mice displayed severe deficits in Schwann cell development and the hypomyelination of peripheral nerves [<xref ref-type="bibr" rid="CR188">188</xref>].</p>
<p id="Par53">There are other NS mouse models in addition to Shp2 mutant mice. Heterozygous <italic>Raf1</italic>-deficient mice display smaller granule cell layer volumes at postnatal day 30 and a substantial number of abnormal, chromophilic, fast dividing cells in the subgranular zone and dentate gyrus [<xref ref-type="bibr" rid="CR105">105</xref>]. In addition, <italic>Raf1</italic>-deficient neural progenitor cells showed an increased rate of cell death and reduced neuronal maturation [<xref ref-type="bibr" rid="CR105">105</xref>]. Recently, Holter and colleagues reported that mice expressing the NS-associated gain of function mutation <italic>Raf1</italic><sup>L613V</sup> have a significantly greater density of GFAP-positive astrocytes in the cortex and hippocampus. In addition, the number of Olig-positive oligodendrocyte progenitor cells were also increased in cortical area of <italic>Raf1</italic><sup>L613V</sup> mutant mice [<xref ref-type="bibr" rid="CR107">107</xref>]. Interestingly, <italic>Raf1</italic><sup>L613V</sup> mice showed enhanced performance in several learning tasks [<xref ref-type="bibr" rid="CR107">107</xref>]. NS-associated <italic>Kras</italic><sup>G12V</sup> mutant mice showed enhanced GABAergic synaptogenesis and impaired spatial learning when the mutation was selectively expressed in synapses [<xref ref-type="bibr" rid="CR99">99</xref>].</p>
<p id="Par54">Although it is known that transcription factors for glial lineage become highly expressed in accordance with increasing RAS-ERK activity [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR108">108</xref>], RAS-activating mutation SHP2<sup>D61G</sup> promotes neuronal lineage rather than glial lineage, by direct interaction with JAK-STAT pathway [<xref ref-type="bibr" rid="CR96">96</xref>]; however, the expression of glial transcription factors that may have been affected by the increase in RAS-ERK activity is yet to be examined. On the contrary, other NS-linked mutations such as <italic>Raf1</italic><sup>L613V</sup> rather enhanced glial lineage [<xref ref-type="bibr" rid="CR107">107</xref>]. Although the underlying mechanism for the discrepancy in cellular phenotypes is not clear, these results suggest that there are distinct pathophysiology according to each NS-associated mutation. It would be interesting to examine the neuron-glia ratio in either NS patient-derived iPSCs or postmortem brain tissues harboring specific <italic>PTPN11</italic> or <italic>RAF1</italic> mutations.</p>
</sec>
<sec id="Sec6">
<title>Cardio-facio-cutaneous syndrome</title>
<p id="Par55">Cardio-facio-cutaneous syndrome (CFCS) is a rare RASopathy that is caused by mutations in the genes that encode downstream effectors of RAS [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], including <italic>BRAF</italic> [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>], <italic>KRAS</italic> [<xref ref-type="bibr" rid="CR41">41</xref>], and <italic>MEK1/2</italic> [<xref ref-type="bibr" rid="CR42">42</xref>]. Importantly, heterozygous <italic>BRAF</italic> mutations are found in over 70% of CFCS patients [<xref ref-type="bibr" rid="CR58">58</xref>]. <italic>BRAF</italic> encodes a serine/threonine kinase, and, interestingly, both the kinase-active and kinase-impaired mutations of <italic>BRAF</italic> are associated with CFCS [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Heterozygous missense mutations in <italic>MEK1</italic> and <italic>MEK2</italic> are found in approximately 25% of CFCS individuals [<xref ref-type="bibr" rid="CR58">58</xref>]. <italic>MEK1</italic> and <italic>MEK2</italic> are threonine/tyrosine kinases, and all the <italic>MEK</italic> mutants associated with CFCS are activating mutations [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR189">189</xref>]. CFCS patients display multiple congenital abnormalities which overlap with those seen in NS and Costello syndrome, including craniofacial defects, hypertrophic cardiomyopathy, pulmonary artery stenosis, and neurocognitive delay [<xref ref-type="bibr" rid="CR58">58</xref>]. CFCS individuals exhibit NS-like faces, with macrocephaly, low-set ears, a short nose, a broad forehead, and down-slanting palpebral fissures with ptosis [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. Cardiac abnormalities are also similar to those of NS and Costello syndrome, with pulmonic stenosis, septal defects, and hypertrophic cardiomyopathy (HCM) having the highest prevalence [<xref ref-type="bibr" rid="CR59">59</xref>]. Neurological abnormalities, including hypotonia, motor delay, seizures, tactile defensiveness, speech delay, and learning disabilities, are present at varying degrees [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Failure to thrive caused by gastrointestinal dysfunction, including vomiting, oral aversion, reflux, and constipation, is also typical in CFCS individuals in infancy [<xref ref-type="bibr" rid="CR50">50</xref>]. However, CNS abnormalities are significant diagnostic features of CFCS. Previous studies reported the abnormalities in brain structures, including ventriculomegaly and hydrocephalus, in CFCS patients [<xref ref-type="bibr" rid="CR44">44</xref>–<xref ref-type="bibr" rid="CR50">50</xref>]. Volume loss in the brain due to cortical atrophy, cerebral atrophy, brain stem atrophy, and white matter atrophy have also emerged in a subpopulation of patients [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR51">51</xref>–<xref ref-type="bibr" rid="CR54">54</xref>]. Additionally, migration abnormalities, myelination abnormalities, and corpus callosum abnormalities, such as hypoplasia and lipoma were also revealed by brain imaging [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR55">55</xref>–<xref ref-type="bibr" rid="CR57">57</xref>]. In line with brain abnormalities, most CFCS patients are diagnosed with varying degrees of cognitive deficits and intellectual disabilities [<xref ref-type="bibr" rid="CR50">50</xref>].</p>
<p id="Par56">Recently, patient-derived induced pluripotent stem cells (iPSCs) have contributed to advancements in the understanding of disease-associated mutations. Yeh and colleagues generated iPSC from a patient harboring <italic>BRAF</italic><sup>Q257R</sup>, the most frequent CFCS mutation [<xref ref-type="bibr" rid="CR190">190</xref>]. This mutation resulted in a depletion of neural progenitor pool, induced by decreased phosphorylation of AKT, and early neuronal maturation [<xref ref-type="bibr" rid="CR190">190</xref>]. Due to the depletion of progenitors, the number of late-born cells, such as the upper-layer cortical neurons and glia, was decreased [<xref ref-type="bibr" rid="CR191">191</xref>]. The number of GABAergic interneurons was increased, indicating that the high prevalence of seizures in CFCS individuals may be caused by an imbalance between excitation and inhibition [<xref ref-type="bibr" rid="CR191">191</xref>].</p>
<p id="Par57">Fewer animal models of CFCS have been reported likely due to its lower prevalence (1 in 810,000) compared to other RASopathies. Transgenic mouse models carrying gain of function mutations that are associated with CFCS recapitulate multiple aspects of human CFCS patients [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR192">192</xref>]. Since <italic>BRAF</italic> is the most prevalent gene that is mutated in CFCS, a majority of animal studies in CFCS have focused on <italic>Braf</italic>. Prior to the review of gain of function mouse models associated with CFCS, we first reviewed loss of function studies that investigated the role of <italic>Braf</italic> in various biological processes. Wiese and colleagues identified that cultured embryonic sensory and motor neurons lacking <italic>Braf</italic> could not survive in the presence of neurotrophic factors while <italic>Raf1</italic>-deficient neurons could survive, suggesting that <italic>Braf</italic> is essential for survival [<xref ref-type="bibr" rid="CR193">193</xref>]. A <italic>Braf</italic> null mutant mouse was embryonically lethal due to the vascular defects at midgestation [<xref ref-type="bibr" rid="CR194">194</xref>]. In addition, the ablation of <italic>Braf</italic> in NSCs using Nestin-Cre resulted in abnormal morphogenesis of the CNS, such as a decreased cerebellum with fuzzy granule cell layer borders and a diminished hippocampus granule cell layer, due to reduced differentiation of dentate gyrus progenitor cells into mature granule cell neurons [<xref ref-type="bibr" rid="CR102">102</xref>]. Nestin-Cre specific <italic>Braf</italic>-deficient mice also displayed severe dysmyelination and defective oligodendrocyte differentiation, implicating <italic>Braf</italic> in postnatal CNS development [<xref ref-type="bibr" rid="CR103">103</xref>]. Forebrain excitatory neuron-specific <italic>Braf</italic> knockout mice showed deficits in hippocampal long-term potentiation and impaired hippocampal-dependent learning and memory, while the impact of <italic>Braf</italic> deletion on CNS development in this knockout remains to be investigated [<xref ref-type="bibr" rid="CR195">195</xref>].</p>
<p id="Par58">The first mutant mouse model of CFCS was a knock-in of the constitutively active form of <italic>Braf</italic>, <italic>Braf</italic><sup>V600E</sup>, which recapitulates several CFCS characteristics, including a reduced life span, growth retardation, facial dysmorphia, cardiomegaly, and epileptic seizures [<xref ref-type="bibr" rid="CR104">104</xref>]. Mice expressing the conditional knock-in <italic>Braf</italic><sup>L597V</sup> mutation also recapitulated CFCS symptoms of a short stature, facial dysmorphia, and cardiac enlargement [<xref ref-type="bibr" rid="CR196">196</xref>]. The most prevalent CFCS mutation, <italic>Braf</italic><sup>Q241R</sup>, induced embryonic/neonatal lethality with multiple congenital defects that included embryonic skeletal abnormalities, lymphatic defects, cardiac defects, and liver necrosis in the C57BL/6J background, and lethality between birth and 24 weeks, growth retardation, sparse and ruffled fur, liver necrosis, and atrial septal defects on the mixed background (BALB/c and C57BL/6J) [<xref ref-type="bibr" rid="CR192">192</xref>, <xref ref-type="bibr" rid="CR197">197</xref>]. In addition, <italic>Braf</italic><sup>Q241R/-</sup> mice showed growth retardation, a hunched appearance, craniofacial dysmorphism, and learning deficits on ICR background [<xref ref-type="bibr" rid="CR192">192</xref>].</p>
<p id="Par59">Mouse models carrying <italic>Mek1</italic><sup>Y130C</sup>, the most common <italic>MEK1</italic> mutation in CFCS patients, showed increased ERK activation in response to growth factors, pulmonary artery stenosis, cranial dysmorphia, and neurological anomalies [<xref ref-type="bibr" rid="CR108">108</xref>]. Moreover, <italic>Mek1</italic><sup>Y130C/Y130C</sup> mice showed a higher density of GFAP-positive astrocytes in the sensory cortex and hippocampal CA1 regions [<xref ref-type="bibr" rid="CR108">108</xref>]. In addition, the total cortical oligodendrocyte population, as analyzed by Olig2 immunolabeling, was increased in the sensory cortex of <italic>Mek1</italic><sup>Y130C/Y130C</sup> mice [<xref ref-type="bibr" rid="CR108">108</xref>]. As addressed earlier, patients-derived iPSC containing <italic>BRAF</italic><sup>Q257R</sup> exhibited early neuronal maturation and decreased late-born glial populations, whereas either CFCS-associated <italic>Mek1</italic><sup>Y130C</sup> or <italic>Braf</italic><sup>V600E</sup> expressing adult mice exhibited an increased number of GFAP-positive cells in hippocampal and cortical areas [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR190">190</xref>]. Although, <italic>BRAF</italic><sup>Q257R</sup> is a gain of function mutation, the activation of ERK was decreased in neural progenitor cells, which might have been due to cell context-dependent role of <italic>BRAF</italic>, and these results indicate that the decreased ERK activation may be responsible for the decreased glia in <italic>BRAF</italic><sup>Q257R</sup> iPSCs [<xref ref-type="bibr" rid="CR190">190</xref>]. In addition to mouse models, zebrafish models expressing CFCS <italic>Braf</italic> or <italic>Mek</italic> variants were also generated, and these CFCS mutant alleles interfered with convergence-extension cell movements during gastrulation to cause similar developmental phenotypes [<xref ref-type="bibr" rid="CR189">189</xref>]. Taken together, each of the CFCS-associated genes play essential roles in CNS development, including oligodendrocyte precursor maturation and proliferation, myelination, and neuronal differentiation. However, our knowledge regarding the causal relationship between CNS abnormalities and cognition in CFCS is still limited. Further studies using mutant animals with more specific temporal and spatial manipulation of CFCS genes would provide understanding of the pathophysiology of cognitive deficits in CFCS.</p>
</sec>
<sec id="Sec7">
<title>Costello syndrome</title>
<p id="Par60">Costello syndrome (CS) is a rare multiple congenital abnormality syndrome that affects 1 in 1,250,000 people and shares many features with other RASopathies [<xref ref-type="bibr" rid="CR198">198</xref>–<xref ref-type="bibr" rid="CR200">200</xref>]. CS is mostly caused by gain of function mutations in the <italic>HRAS</italic> gene, most of which have been previously reported as somatic or oncogenic mutations in various tumors [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR201">201</xref>]. <italic>HRAS</italic> activating mutations are highly prevalent in CS individuals; they disrupt guanine nucleotide binding and induce a decrease in intrinsic and GAP-induced GTPase activity, allowing mutant HRAS proteins to remain in the active state [<xref ref-type="bibr" rid="CR202">202</xref>]. In addition, <italic>BRAF</italic>, <italic>KRAS</italic>, and <italic>MEK1</italic> mutations are also associated with a small population of CS individuals [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR203">203</xref>]. CS patients are typical characterized by coarse facial features, redundant and loose skin, severe failure to thrive, mental retardation, cardiomyopathy, and a predisposition to tumors [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. There is no single feature that is unique to CS, and this syndrome phenotypically overlaps with NF1, NS, NSML, and CFCS [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR204">204</xref>]. Typical and coarse facial features associated with CS involve macrocephaly with a prominent forehead, a short nose with a depressed nasal bridge and a broad base, and low-set, posteriorly rotated ears with thickened helices and lobes. Most CS patients have cardiac abnormalities, including hypertrophic cardiomyopathy, valve abnormalities, septal defects, and arrhythmia [<xref ref-type="bibr" rid="CR205">205</xref>]. Failure to thrive due to gastrointestinal dysfunction often involves reflux, oral aversion, and constipation during early infancy [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR200">200</xref>]. Structural and electrophysiological neurological malformations are also common in CS. For example, ventricular abnormalities, such as mild ventricular dilatation, are observed in more than 40% of CS individuals [<xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR67">67</xref>]. Cerebral malformations in CS include cerebral atrophy, leukomalacia, poor gray-white matter differentiation, a small corpus callosum, and MRI signal abnormalities [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR67">67</xref>–<xref ref-type="bibr" rid="CR71">71</xref>]. Cerebellar abnormalities include malformation, cerebellar atrophy, deviation of the cerebellar tonsils, and demyelinization of the basal tonsil [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR71">71</xref>–<xref ref-type="bibr" rid="CR74">74</xref>].</p>
<p id="Par61">Krencik and colleagues have shown that human iPSCs carrying <italic>HRAS</italic><sup>G12S</sup> that were derived from CS patients exhibited hyperplasia and differentiated into astroglia more rapidly in vitro than iPSCs derived from control cell lines with normal <italic>HRAS</italic>. CS-derived iPSCs also generated an abundance of extracellular matrix remodeling factors and proteoglycans [<xref ref-type="bibr" rid="CR206">206</xref>]. Moreover, <italic>HRAS</italic><sup>G12S</sup> iPSC-derived neurons had a longer progenitor phase, unlike the phenotype reported in <italic>BRAF</italic><sup>Q257R</sup> iPSC-derived neurons that originated from CFCS patients [<xref ref-type="bibr" rid="CR190">190</xref>, <xref ref-type="bibr" rid="CR207">207</xref>]. Thus, postnatal progressive cerebellar overgrowth of the brain in CS individuals could be caused by the extended progenitor phase [<xref ref-type="bibr" rid="CR208">208</xref>].</p>
<p id="Par62">As with CFCS, only few animal models were generated for CS. Both homozygous and heterozygous <italic>Hras</italic><sup>G12V</sup> knock-in mice closely phenocopied some of the features observed in individuals with CS, including facial dysmorphia, cardiomyopathies, and alterations to the homeostasis of the cardiovascular system [<xref ref-type="bibr" rid="CR209">209</xref>]. In addition, later studies with homozygous <italic>Hras</italic><sup>G12V</sup> knock-in mice demonstrated that they have neurocognitive deficits, such as hyperactivity, increased anxiety-like behavior and mild deficit in spatial memory [<xref ref-type="bibr" rid="CR210">210</xref>]. However, Viosca and colleagues did not observe significant changes in either the activity or the expression of downstream of <italic>Hras</italic> such as phospho-CREB and <italic>c-fos</italic> [<xref ref-type="bibr" rid="CR210">210</xref>]. Transgenic mice with forebrain excitatory neuron-specific expression of <italic>Hras</italic><sup>G12V</sup> under the control of the αCaMKII promoter displayed several synaptic phenotypes, including a high density of docked neurotransmitter vesicles in glutamatergic terminals and increased synaptic plasticity which may be associated with the dramatically enhanced hippocampal-dependent learning [<xref ref-type="bibr" rid="CR101">101</xref>]. Schreiber and colleagues have also shown that the homozygous <italic>Hras</italic><sup>G12V</sup> knock-in mice exhibit spatial learning deficits, which are accompanied by robust upregulation of Erk signaling in hippocampal lysates, neuronal hypertrophy, increased brain volume, and impaired mGluR-dependent long-term depression (LTD) [<xref ref-type="bibr" rid="CR100">100</xref>]. Notably, mice expressing CS-associated <italic>Hras</italic><sup>G12V</sup> or <italic>Hras</italic><sup>G12S</sup> mutations in cortical precursors displayed promoted precursor cell proliferation and premature gliogenesis, but inhibited neurogenesis [<xref ref-type="bibr" rid="CR211">211</xref>]. Consistently, either form of <italic>Hras</italic> mutations also promoted precursor cell proliferation and astrogenesis, but inhibited neurogenesis in cultured cortical precursors [<xref ref-type="bibr" rid="CR211">211</xref>]. These findings from multiple experimental systems such as iPSCs, mice models and cultured cells commonly suggest the essential role of <italic>HRAS</italic> in neural precursor cell proliferation and gliogenesis, which might strongly affect the structure and function of CNS including increased brain volume in CS patients.</p>
</sec>
</sec>
</sec>
<sec id="Sec8">
<title>Concluding remarks</title>
<p id="Par63">Here, we reviewed that mutations in different components of the RAS-ERK signaling pathway associated with different RASopathies have distinct impacts on CNS development in a cell type-specific manner (Fig. <xref ref-type="fig" rid="Fig2">2</xref>). However, it is still unclear how some mutations affect neurons and others affect glia. One hypothesis is that different signaling molecules are expressed at distinct phases during development. So far, we do not have the expression profiles of RAS signaling molecules during brain development in high spatial and temporal resolution. However, most of the key RAS-ERK components, such as NF1, SHP2, BRAF, and MEK1/2, begin to be expressed before either embryonic day 10 or 15, which are initiation time points of neurogenesis or astrogliogenesis, respectively [<xref ref-type="bibr" rid="CR212">212</xref>]. Recently, it has been shown that the expression of RAS-ERK signaling molecules was remarkably different between excitatory and inhibitory neurons in mouse hippocampus [<xref ref-type="bibr" rid="CR162">162</xref>]. Thus, it would be interesting to examine whether the expression levels of various signaling molecules are differentially regulated in NSCs over different developmental stages. Advanced tools, such as single cell RNA-seq, might be useful to answer this question. It should also be considered that there are multiple cross-talks between RAS and other signaling pathways. Different components in RAS signaling interact with distinct signaling networks, which may account for the cell type-specific developmental deficits in each RASopathy.
<fig id="Fig2"><label>Fig. 2</label><caption><p>Effect of RAS signaling components on neural stem cell differentiation. Neural stem cells are able to generate progeny cells that terminally differentiate into neurons, oligodendrocytes, and astrocytes. <bold>a</bold> NF1 inactivation led to decreased neurogenesis in neonatal and adult mouse brains [<xref ref-type="bibr" rid="CR85">85</xref>]. PTPN11 positively regulates neurogenesis at the expense of gliogenesis [<xref ref-type="bibr" rid="CR96">96</xref>]. <bold>b</bold> NF1 negatively regulates gliogenesis, thus NF1 inactivation increases the number of glial progenitor cells and gliogenesis [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR160">160</xref>]. PTPN11 suppresses gliogenesis by directly interacting with the JAK-STAT pathway, which promotes gliogenesis [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR96">96</xref>]. <bold>c</bold> Hyperactivation of RAF1 induces the increase of glial lineage populations, including oligodendrocyte progenitor cells and astrocytes [<xref ref-type="bibr" rid="CR107">107</xref>]. MEK is required for gliogenesis, and the hyperfunction of MEK1 leads to increase in glial populations [<xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR109">109</xref>]. <bold>d</bold> BRAF and RAF1 positively regulate neuronal differentiation, and the disruption of BRAF or RAF1 impairs the ability of progenitor cells to differentiate into mature neurons in mouse brain [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. In consistent, iPSC containing hyperactivated BRAF mutant showed early maturation of neurons [<xref ref-type="bibr" rid="CR190">190</xref>]. <bold>e</bold> Oligodendroglial lineage potential is restricted by NF1 in the adult hippocampus, and inactivation of NF1 allows the adult hippocampus to generate oligodendrocytes [<xref ref-type="bibr" rid="CR85">85</xref>]. <bold>f</bold> BRAF is required for oligodendrocyte maturation and myelination during postnatal development [<xref ref-type="bibr" rid="CR103">103</xref>]. <bold>g</bold> Hyperactivated HRAS leads to an acceleration of astroglial maturation [<xref ref-type="bibr" rid="CR206">206</xref>, <xref ref-type="bibr" rid="CR211">211</xref>]. Blue and red arrows indicate positive and negative regulation, respectively.</p></caption><graphic id="MO2" xlink:href="13041_2019_517_Fig2_HTML"></graphic></fig></p>
<p id="Par64">Treatments for the cognitive deficits found in RASopathies are not available yet. Since most RASopathy-associated mutations increase RAS-ERK activation, downregulating the activity of RAS or its downstream effectors is an obvious strategy to develop treatments for RASopathies. Although statins, which can reduce RAS activity by inhibiting the farnesylation of RAS, have been proposed for the improvement of learning disabilities in NF1 children [<xref ref-type="bibr" rid="CR213">213</xref>], the results from various clinical trials have been inconsistent [<xref ref-type="bibr" rid="CR214">214</xref>–<xref ref-type="bibr" rid="CR216">216</xref>]. The reason for these discrepant results remains unclear. However, considering the ubiquitous expression of RAS in many cell types and multiple organs, directly regulating RAS activity may have unknown confounding effects. Thus, it would be better to target specific molecules other than RAS in a disease-specific manner. For example, Omrani and colleagues showed that inhibitory neuron-specific attenuation of hyperpolarization-activated cyclic nucleotide-gated (HCN) currents can be an underlying mechanism for the cognitive deficits in <italic>Nf1</italic><sup>+/-</sup> mice when they used an HCN agonist to rescue cognitive deficits in <italic>Nf1</italic><sup>+/-</sup> mice [<xref ref-type="bibr" rid="CR217">217</xref>]. Recently, Ryu and colleagues showed that selectively reducing the interaction between mutant SHP2 and Gab1 in excitatory neurons reversed the physiological and behavioral deficits in a mouse model of NS [<xref ref-type="bibr" rid="CR162">162</xref>]. Conditional mutant mice with higher spatial and temporal resolution will provide clues when, where, and which cell types are most suited for interventions.</p>
<p id="Par65">Lastly, it should be noted that most of the RASopathy mechanism studies have used mice as a model system. Mouse models have many advantages and can be used to study neuropsychiatric disorders because the majority of neuropsychiatric drugs used in humans were shown to be, at least partially, effective in mouse models [<xref ref-type="bibr" rid="CR218">218</xref>]. However, caution is still warranted. Nowadays, it has become relatively easy to model diseases in vitro using iPSC and several iPSC lines are available to study RASopathies, allowing for parallel and comparative analyses in vitro and in vivo.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>Ascl1</term>
<def>
<p id="Par2">Achaete scute-like 1</p>
</def>
</def-item>
<def-item>
<term>BLBP</term>
<def>
<p id="Par3">Brain lipid binding protein</p>
</def>
</def-item>
<def-item>
<term>CFCS</term>
<def>
<p id="Par4">Cardio-facio-cutaneous syndrome</p>
</def>
</def-item>
<def-item>
<term>CKO</term>
<def>
<p id="Par5">Conditional knockout</p>
</def>
</def-item>
<def-item>
<term>CNS</term>
<def>
<p id="Par6">Central nervous system</p>
</def>
</def-item>
<def-item>
<term>CS</term>
<def>
<p id="Par7">Costello syndrome</p>
</def>
</def-item>
<def-item>
<term>ERK</term>
<def>
<p id="Par8">Extracellular signal-regulated kinase</p>
</def>
</def-item>
<def-item>
<term>GABAergic</term>
<def>
<p id="Par9">Gamma-aminobutyric acidergic</p>
</def>
</def-item>
<def-item>
<term>GAPs</term>
<def>
<p id="Par10">GTPase activating proteins</p>
</def>
</def-item>
<def-item>
<term>GEFs</term>
<def>
<p id="Par11">Guanine nucleotide exchange factors</p>
</def>
</def-item>
<def-item>
<term>GFAP</term>
<def>
<p id="Par12">Glial fibrillary acidic protein</p>
</def>
</def-item>
<def-item>
<term>GNPs</term>
<def>
<p id="Par13">Granule neuron progenitors</p>
</def>
</def-item>
<def-item>
<term>HCM</term>
<def>
<p id="Par14">Hypertrophic cardiomyopathy</p>
</def>
</def-item>
<def-item>
<term>iPSCs</term>
<def>
<p id="Par15">Induced pluripotent stem cells</p>
</def>
</def-item>
<def-item>
<term>JAK</term>
<def>
<p id="Par16">Janus kinase</p>
</def>
</def-item>
<def-item>
<term>KRAS</term>
<def>
<p id="Par17">Kirsten rat sarcoma viral oncogene homolog</p>
</def>
</def-item>
<def-item>
<term>MEK1/2</term>
<def>
<p id="Par18">MAPK/ERK kinase 1/2</p>
</def>
</def-item>
<def-item>
<term>Neurog2</term>
<def>
<p id="Par19">Neurogenin 2</p>
</def>
</def-item>
<def-item>
<term>NF1</term>
<def>
<p id="Par20">Neurofibromatosis type 1</p>
</def>
</def-item>
<def-item>
<term>NRAS</term>
<def>
<p id="Par21">Neuroblastoma RAS viral oncogene homolog</p>
</def>
</def-item>
<def-item>
<term>NS</term>
<def>
<p id="Par22">Noonan syndrome</p>
</def>
</def-item>
<def-item>
<term>NSCs</term>
<def>
<p id="Par23">Neural stem cells</p>
</def>
</def-item>
<def-item>
<term>NSML</term>
<def>
<p id="Par24">Noonan syndrome with multiple lentigines</p>
</def>
</def-item>
<def-item>
<term>PI3K</term>
<def>
<p id="Par25">Phosphatidylinositol 3-kinase</p>
</def>
</def-item>
<def-item>
<term>PTPN11</term>
<def>
<p id="Par26">Protein tyrosine phosphatase non-receptor type 11</p>
</def>
</def-item>
<def-item>
<term>RTKs</term>
<def>
<p id="Par27">Receptor tyrosine kinases</p>
</def>
</def-item>
<def-item>
<term>SHOC2</term>
<def>
<p id="Par28">Soc-2 suppressor of clear homolog</p>
</def>
</def-item>
<def-item>
<term>SOS1</term>
<def>
<p id="Par29">Son of sevenless homolog 1</p>
</def>
</def-item>
<def-item>
<term>STAT</term>
<def>
<p id="Par30">Signal transducer and activator of transcription</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Publisher’s Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgements</title>
<p>Authors thank Jae Yoon Hwang for proofreading the manuscript and all the members of laboratory of neurophysiology for their comments on the manuscript.</p>
</ack>
<notes notes-type="author-contribution">
<title>Authors' contributions</title>
<p>Y-SL and MK contributed to conception. MK and Y-SL reviewed the literatures and wrote the manuscript. MK generated figures and tables. Both authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>This work was supported by the NRF-2016H1A2A1907206 grant to M.K. and the NRF-2019R1A2C1084232, NRF-2019R1A4A2001609 and NRF-2017M3C7A1026959 grants to Y.-S.L.</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>Not applicable</p>
</notes>
<notes>
<title>Ethics approval and consent to participate</title>
<p id="Par66">Not applicable</p>
</notes>
<notes>
<title>Consent for publication</title>
<p id="Par67">Not applicable</p>
</notes>
<notes notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par68">The authors declare that they have no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolch</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions</article-title>
<source/>Biochem J
          <year>2000</year>
<volume>351</volume>
<issue>Pt 2</issue>
<fpage>289</fpage>
<lpage>305</lpage>
<pub-id pub-id-type="doi">10.1042/bj3510289</pub-id>
<pub-id pub-id-type="pmid">11023813</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boguski</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>McCormick</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Proteins regulating Ras and its relatives</article-title>
<source/>Nature.
          <year>1993</year>
<volume>366</volume>
<fpage>643</fpage>
<lpage>654</lpage>
<pub-id pub-id-type="doi">10.1038/366643a0</pub-id>
<pub-id pub-id-type="pmid">8259209</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryu</surname>
<given-names>Hyun-Hee</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Yong-Seok</given-names>
</name>
</person-group>
<article-title>Cell type-specific roles of RAS-MAPK signaling in learning and memory: Implications in neurodevelopmental disorders</article-title>
<source/>Neurobiology of Learning and Memory
          <year>2016</year>
<volume>135</volume>
<fpage>13</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.nlm.2016.06.006</pub-id>
<pub-id pub-id-type="pmid">27296701</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rauen</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>The RASopathies</article-title>
<source/>Annu Rev Genomics Hum Genet
          <year>2013</year>
<volume>14</volume>
<fpage>355</fpage>
<lpage>369</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-genom-091212-153523</pub-id>
<pub-id pub-id-type="pmid">23875798</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Innocenti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tenca</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Frittoli</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Faretta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tocchetti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Di Fiore</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Scita</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Mechanisms through which Sos-1 coordinates the activation of Ras and Rac</article-title>
<source/>J Cell Biol
          <year>2002</year>
<volume>156</volume>
<fpage>125</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200108035</pub-id>
<pub-id pub-id-type="pmid">11777939</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brinton</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>Vasopressin-induced cytoplasmic and nuclear calcium signaling in embryonic cortical astrocytes: dynamics of calcium and calcium-dependent kinase translocation</article-title>
<source/>J Neurosci
          <year>2003</year>
<volume>23</volume>
<fpage>4228</fpage>
<lpage>4239</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-10-04228.2003</pub-id>
<pub-id pub-id-type="pmid">12764111</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Clifton</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Lucocq</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Alessi</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB</article-title>
<source/>EMBO J
          <year>1998</year>
<volume>17</volume>
<fpage>4426</fpage>
<lpage>4441</lpage>
<pub-id pub-id-type="doi">10.1093/emboj/17.15.4426</pub-id>
<pub-id pub-id-type="pmid">9687510</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shilyansky</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Molecular and cellular mechanisms of learning disabilities: a focus on NF1</article-title>
<source/>Annu Rev Neurosci
          <year>2010</year>
<volume>33</volume>
<fpage>221</fpage>
<lpage>243</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-neuro-060909-153215</pub-id>
<pub-id pub-id-type="pmid">20345245</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>YE</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>ST</given-names>
</name>
</person-group>
<article-title>Neurodevelopmental Aspects of RASopathies</article-title>
<source/>Mol Cells
          <year>2019</year>
<volume>42</volume>
<fpage>441</fpage>
<lpage>447</lpage>
<pub-id pub-id-type="pmid">31250618</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tidyman</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation</article-title>
<source/>Curr Opin Genet Dev
          <year>2009</year>
<volume>19</volume>
<fpage>230</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1016/j.gde.2009.04.001</pub-id>
<pub-id pub-id-type="pmid">19467855</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jindal</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Burdine</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Shvartsman</surname>
<given-names>SY</given-names>
</name>
</person-group>
<article-title>RASopathies: unraveling mechanisms with animal models</article-title>
<source/>Dis Model Mech
          <year>2015</year>
<volume>8</volume>
<fpage>769</fpage>
<lpage>782</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.020339</pub-id>
<pub-id pub-id-type="pmid">26203125</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferner</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Huson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Willshaw</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Upadhyaya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Towers</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gleeson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Steiger</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Guidelines for the diagnosis and management of individuals with neurofibromatosis 1</article-title>
<source/>J Med Genet
          <year>2007</year>
<volume>44</volume>
<fpage>81</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2006.045906</pub-id>
<pub-id pub-id-type="pmid">17105749</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosman</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Pearce</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The brain in multiple neurofibromatosis (von Recklinghausen's disease): a suggested neuropathological basis for the associated mental defect</article-title>
<source/>Brain
          <year>1967</year>
<volume>90</volume>
<fpage>829</fpage>
<lpage>838</lpage>
<pub-id pub-id-type="doi">10.1093/brain/90.4.829</pub-id>
<pub-id pub-id-type="pmid">4965489</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Listernick</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Charrow</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Greenwald</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Esterly</surname>
<given-names>NB</given-names>
</name>
</person-group>
<article-title>Optic gliomas in children with neurofibromatosis type 1</article-title>
<source/>J Pediatr
          <year>1989</year>
<volume>114</volume>
<fpage>788</fpage>
<lpage>792</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-3476(89)80137-4</pub-id>
<pub-id pub-id-type="pmid">2497236</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krab</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Aarsen</surname>
<given-names>FK</given-names>
</name>
<name>
<surname>de Goede-Bolder</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Catsman-Berrevoets</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Arts</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Moll</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Elgersma</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Impact of neurofibromatosis type 1 on school performance</article-title>
<source/>J Child Neurol
          <year>2008</year>
<volume>23</volume>
<fpage>1002</fpage>
<lpage>1010</lpage>
<pub-id pub-id-type="doi">10.1177/0883073808316366</pub-id>
<pub-id pub-id-type="pmid">18827266</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shilyansky</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Karlsgodt</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Sidiropoulou</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hardt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>James</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Ehninger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bearden</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Poirazi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jentsch</surname>
<given-names>JD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurofibromin regulates corticostriatal inhibitory networks during working memory performance</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2010</year>
<volume>107</volume>
<fpage>13141</fpage>
<lpage>13146</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1004829107</pub-id>
<pub-id pub-id-type="pmid">20624961</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cichowski</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jacks</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>NF1 tumor suppressor gene function: narrowing the GAP</article-title>
<source/>Cell.
          <year>2001</year>
<volume>104</volume>
<fpage>593</fpage>
<lpage>604</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(01)00245-8</pub-id>
<pub-id pub-id-type="pmid">11239415</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>LF</given-names>
</name>
</person-group>
<article-title>Neurofibromin, a tumor suppressor in the nervous system</article-title>
<source/>Exp Cell Res
          <year>2001</year>
<volume>264</volume>
<fpage>19</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1006/excr.2000.5138</pub-id>
<pub-id pub-id-type="pmid">11237520</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brems</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Legius syndrome, an Update. Molecular pathology of mutations in SPRED1</article-title>
<source/>Keio J Med
          <year>2013</year>
<volume>62</volume>
<fpage>107</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="doi">10.2302/kjm.2013-0002-RE</pub-id>
<pub-id pub-id-type="pmid">24334617</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Babcock</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Maria</surname>
<given-names>BL</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis type 1 revisited</article-title>
<source/>Pediatrics.
          <year>2009</year>
<volume>123</volume>
<fpage>124</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1542/peds.2007-3204</pub-id>
<pub-id pub-id-type="pmid">19117870</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tartaglia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kalidas</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Musat</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>van der Burgt</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Brunner</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Bertola</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Crosby</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ion</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity</article-title>
<source/>Am J Hum Genet
          <year>2002</year>
<volume>70</volume>
<fpage>1555</fpage>
<lpage>1563</lpage>
<pub-id pub-id-type="doi">10.1086/340847</pub-id>
<pub-id pub-id-type="pmid">11992261</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Razzaque</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Nishizawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Komoike</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yagi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Furutani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Amo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kamisago</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Momma</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Katayama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Germline gain-of-function mutations in RAF1 cause Noonan syndrome</article-title>
<source/>Nat Genet
          <year>2007</year>
<volume>39</volume>
<fpage>1013</fpage>
<lpage>1017</lpage>
<pub-id pub-id-type="doi">10.1038/ng2078</pub-id>
<pub-id pub-id-type="pmid">17603482</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandit</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sarkozy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pennacchio</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Carta</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Oishi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pogna</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Schackwitz</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ustaszewska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Landstrom</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy</article-title>
<source/>Nat Genet
          <year>2007</year>
<volume>39</volume>
<fpage>1007</fpage>
<lpage>1012</lpage>
<pub-id pub-id-type="doi">10.1038/ng2073</pub-id>
<pub-id pub-id-type="pmid">17603483</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tartaglia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pennacchio</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yadav</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Fodale</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sarkozy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pandit</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Oishi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schackwitz</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome</article-title>
<source/>Nat Genet
          <year>2007</year>
<volume>39</volume>
<fpage>75</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1038/ng1939</pub-id>
<pub-id pub-id-type="pmid">17143282</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schubbert</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zenker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Boll</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bollag</surname>
<given-names>G</given-names>
</name>
<name>
<surname>van der Burgt</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Musante</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kalscheuer</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wehner</surname>
<given-names>LE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Germline KRAS mutations cause Noonan syndrome</article-title>
<source/>Nat Genet
          <year>2006</year>
<volume>38</volume>
<fpage>331</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="doi">10.1038/ng1748</pub-id>
<pub-id pub-id-type="pmid">16474405</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carta</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pantaleoni</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bocchinfuso</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Stella</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vasta</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Sarkozy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Digilio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Palleschi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pizzuti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Grammatico</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype</article-title>
<source/>Am J Hum Genet
          <year>2006</year>
<volume>79</volume>
<fpage>129</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.1086/504394</pub-id>
<pub-id pub-id-type="pmid">16773572</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nava</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hanna</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Michot</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pouvreau</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Niihori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Matsubara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Arveiler</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lacombe</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome</article-title>
<source/>J Med Genet
          <year>2007</year>
<volume>44</volume>
<fpage>763</fpage>
<lpage>771</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2007.050450</pub-id>
<pub-id pub-id-type="pmid">17704260</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peiris</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Chiari (type 1) malformation and syringomyelia in a patient with Noonan's syndrome</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>1982</year>
<volume>45</volume>
<fpage>753</fpage>
<lpage>754</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.45.8.753</pub-id>
<pub-id pub-id-type="pmid">7131003</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Aikawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takemiya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takano</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Noonan’s syndrome with syringomyelia</article-title>
<source/>Jpn J Psychiatry Neurol
          <year>1986</year>
<volume>40</volume>
<fpage>101</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="pmid">3773346</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorke</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Cerebral defects in Noonan's syndrome (author's transl)</article-title>
<source/>Klin Padiatr
          <year>1980</year>
<volume>192</volume>
<fpage>577</fpage>
<lpage>581</lpage>
<pub-id pub-id-type="doi">10.1055/s-2008-1035646</pub-id>
<pub-id pub-id-type="pmid">7194399</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noonan</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease</article-title>
<source/>Am J Dis Child
          <year>1968</year>
<volume>116</volume>
<fpage>373</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.1001/archpedi.1968.02100020377005</pub-id>
<pub-id pub-id-type="pmid">4386970</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raman Unnithan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bahuleyan</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Matnew Roy</surname>
<given-names>VC</given-names>
</name>
</person-group>
<article-title>Noonan syndrome</article-title>
<source/>J Assoc Physicians India
          <year>1985</year>
<volume>33</volume>
<fpage>177</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="pmid">3997763</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hanaoka</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sugai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>A case of Noonan syndrome with cortical dysplasia</article-title>
<source/>Pediatr Neurol
          <year>1997</year>
<volume>17</volume>
<fpage>266</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1016/S0887-8994(97)00094-5</pub-id>
<pub-id pub-id-type="pmid">9390707</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cesarini</surname>
<given-names>Laura</given-names>
</name>
<name>
<surname>Alfieri</surname>
<given-names>Paolo</given-names>
</name>
<name>
<surname>Pantaleoni</surname>
<given-names>Francesca</given-names>
</name>
<name>
<surname>Vasta</surname>
<given-names>Isabella</given-names>
</name>
<name>
<surname>Cerutti</surname>
<given-names>Marta</given-names>
</name>
<name>
<surname>Petrangeli</surname>
<given-names>Valentina</given-names>
</name>
<name>
<surname>Mariotti</surname>
<given-names>Paolo</given-names>
</name>
<name>
<surname>Leoni</surname>
<given-names>Chiara</given-names>
</name>
<name>
<surname>Ricci</surname>
<given-names>Daniela</given-names>
</name>
<name>
<surname>Vicari</surname>
<given-names>Stefano</given-names>
</name>
<name>
<surname>Selicorni</surname>
<given-names>Angelo</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>Marco</given-names>
</name>
<name>
<surname>Mercuri</surname>
<given-names>Eugenio</given-names>
</name>
<name>
<surname>Zampino</surname>
<given-names>Giuseppe</given-names>
</name>
</person-group>
<article-title>Cognitive profile of disorders associated with dysregulation of the RAS/MAPK signaling cascade</article-title>
<source/>American Journal of Medical Genetics Part A
          <year>2009</year>
<volume>149A</volume>
<issue>2</issue>
<fpage>140</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.32488</pub-id>
<pub-id pub-id-type="pmid">19133693</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pierpont</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Pierpont</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Mendelsohn</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Tworog-Dube</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Seidenberg</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Genotype differences in cognitive functioning in Noonan syndrome</article-title>
<source/>Genes Brain Behav
          <year>2009</year>
<volume>8</volume>
<fpage>275</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1111/j.1601-183X.2008.00469.x</pub-id>
<pub-id pub-id-type="pmid">19077116</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Niihori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Banjo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kurosawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ogata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takada</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome</article-title>
<source/>Am J Hum Genet
          <year>2013</year>
<volume>93</volume>
<fpage>173</fpage>
<lpage>180</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2013.05.021</pub-id>
<pub-id pub-id-type="pmid">23791108</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Portnoy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Patton</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Psychological profile of children with Noonan syndrome</article-title>
<source/>Dev Med Child Neurol
          <year>2005</year>
<volume>47</volume>
<fpage>35</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.2005.tb01037.x</pub-id>
<pub-id pub-id-type="pmid">15686287</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Razzaque</surname>
<given-names>Md. Abdur</given-names>
</name>
<name>
<surname>Komoike</surname>
<given-names>Yuta</given-names>
</name>
<name>
<surname>Nishizawa</surname>
<given-names>Tsutomu</given-names>
</name>
<name>
<surname>Inai</surname>
<given-names>Kei</given-names>
</name>
<name>
<surname>Furutani</surname>
<given-names>Michiko</given-names>
</name>
<name>
<surname>Higashinakagawa</surname>
<given-names>Toru</given-names>
</name>
<name>
<surname>Matsuoka</surname>
<given-names>Rumiko</given-names>
</name>
</person-group>
<article-title>Characterization of a novel KRAS mutation identified in Noonan syndrome</article-title>
<source/>American Journal of Medical Genetics Part A
          <year>2012</year>
<volume>158A</volume>
<issue>3</issue>
<fpage>524</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.34419</pub-id>
<pub-id pub-id-type="pmid">22302539</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roberts</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Allanson</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gelb</surname>
<given-names>BD</given-names>
</name>
</person-group>
<article-title>Noonan syndrome</article-title>
<source/>Lancet
          <year>2013</year>
<volume>381</volume>
<fpage>333</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(12)61023-X</pub-id>
<pub-id pub-id-type="pmid">23312968</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Burgt</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Thoonen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Roosenboom</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Assman-Hulsmans</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gabreels</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Otten</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Brunner</surname>
<given-names>HG</given-names>
</name>
</person-group>
<article-title>Patterns of cognitive functioning in school-aged children with Noonan syndrome associated with variability in phenotypic expression</article-title>
<source/>J Pediatr
          <year>1999</year>
<volume>135</volume>
<fpage>707</fpage>
<lpage>713</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-3476(99)70089-2</pub-id>
<pub-id pub-id-type="pmid">10586173</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niihori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Narumi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Neri</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cave</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Verloes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hennekam</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Gillessen-Kaesbach</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wieczorek</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome</article-title>
<source/>Nat Genet
          <year>2006</year>
<volume>38</volume>
<fpage>294</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="doi">10.1038/ng1749</pub-id>
<pub-id pub-id-type="pmid">16474404</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez-Viciana</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tetsu</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Tidyman</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Estep</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Conger</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Cruz</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>McCormick</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome</article-title>
<source/>Science
          <year>2006</year>
<volume>311</volume>
<fpage>1287</fpage>
<lpage>1290</lpage>
<pub-id pub-id-type="doi">10.1126/science.1124642</pub-id>
<pub-id pub-id-type="pmid">16439621</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narumi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Niihori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Neri</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cave</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Verloes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nava</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kavamura</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kurosawa</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome</article-title>
<source/>Am J Med Genet A
          <year>2007</year>
<volume>143a</volume>
<fpage>799</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.31658</pub-id>
<pub-id pub-id-type="pmid">17366577</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reynolds</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Neri</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Blumberg</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Coldwell</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Miles</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Opitz</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement--the CFC syndrome</article-title>
<source/>Am J Med Genet
          <year>1986</year>
<volume>25</volume>
<fpage>413</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320250303</pub-id>
<pub-id pub-id-type="pmid">3789005</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neri</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sabatino</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bertini</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Genuardi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The CFC syndrome--report of the first two cases outside the United States</article-title>
<source/>Am J Med Genet
          <year>1987</year>
<volume>27</volume>
<fpage>767</fpage>
<lpage>771</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320270404</pub-id>
<pub-id pub-id-type="pmid">3425595</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chrzanowska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fryns</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Van den Berghe</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Cardio-facio-cutaneous (CFC) syndrome: report of a new patient</article-title>
<source/>Am J Med Genet
          <year>1989</year>
<volume>33</volume>
<fpage>471</fpage>
<lpage>473</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320330410</pub-id>
<pub-id pub-id-type="pmid">2596505</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ades</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Sillence</surname>
<given-names>DO</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Cardiofaciocutaneous syndrome</article-title>
<source/>Clin Dysmorphol
          <year>1992</year>
<volume>1</volume>
<fpage>145</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="pmid">1342862</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Ziylan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schaffer</surname>
<given-names>DB</given-names>
</name>
</person-group>
<article-title>The ophthalmologic manifestations of the cardio-facio-cutaneous syndrome</article-title>
<source/>J Pediatr Ophthalmol Strabismus
          <year>1993</year>
<volume>30</volume>
<fpage>48</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">8455127</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krajewska-Walasek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chrzanowska</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jastrzbska</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The cardio-facio-cutaneous (CFC) syndrome--two possible new cases and review of the literature</article-title>
<source/>Clin Dysmorphol
          <year>1996</year>
<volume>5</volume>
<fpage>65</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1097/00019605-199601000-00010</pub-id>
<pub-id pub-id-type="pmid">8867662</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Blaser</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>Neurological complications of cardio-facio-cutaneous syndrome</article-title>
<source/>Dev Med Child Neurol
          <year>2007</year>
<volume>49</volume>
<fpage>894</fpage>
<lpage>899</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.2007.00894.x</pub-id>
<pub-id pub-id-type="pmid">18039235</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Somer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Peippo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aalto-Korte</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ritvanen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Niemi</surname>
<given-names>KM</given-names>
</name>
</person-group>
<article-title>Cardio-facio-cutaneous syndrome: three additional cases and review of the literature</article-title>
<source/>Am J Med Genet
          <year>1992</year>
<volume>44</volume>
<fpage>691</fpage>
<lpage>695</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320440531</pub-id>
<pub-id pub-id-type="pmid">1481834</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grebe</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Clericuzio</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Neurologic and gastrointestinal dysfunction in cardio-facio-cutaneous syndrome: identification of a severe phenotype</article-title>
<source/>Am J Med Genet
          <year>2000</year>
<volume>95</volume>
<fpage>135</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="doi">10.1002/1096-8628(20001113)95:2&lt;135::AID-AJMG8&gt;3.0.CO;2-J</pub-id>
<pub-id pub-id-type="pmid">11078563</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manci</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Horenstein</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mancao</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Gremse</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Nimityongskul</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Maertens</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cardiofaciocutaneous syndrome (CFC) with congenital peripheral neuropathy and nonorganic malnutrition: an autopsy study</article-title>
<source/>Am J Med Genet A
          <year>2005</year>
<volume>137</volume>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.30834</pub-id>
<pub-id pub-id-type="pmid">16007634</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baraitser</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Patton</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>A Noonan-like short stature syndrome with sparse hair</article-title>
<source/>J Med Genet
          <year>1986</year>
<volume>23</volume>
<fpage>161</fpage>
<lpage>164</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.23.2.161</pub-id>
<pub-id pub-id-type="pmid">3712393</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armour</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Allanson</surname>
<given-names>JE</given-names>
</name>
</person-group>
<article-title>Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations</article-title>
<source/>J Med Genet
          <year>2008</year>
<volume>45</volume>
<fpage>249</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2007.054460</pub-id>
<pub-id pub-id-type="pmid">18039946</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papadopoulou</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sifakis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sol-Church</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Klein-Zighelboim</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Stabley</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Raissaki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gripp</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Kalmanti</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>CNS imaging is a key diagnostic tool in the evaluation of patients with CFC syndrome: two cases and literature review</article-title>
<source/>Am J Med Genet A
          <year>2011</year>
<volume>155a</volume>
<fpage>605</fpage>
<lpage>611</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.33787</pub-id>
<pub-id pub-id-type="pmid">21337689</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wieczorek</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Majewski</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gillessen-Kaesbach</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Cardio-facio-cutaneous (CFC) syndrome--a distinct entity? Report of three patients demonstrating the diagnostic difficulties in delineation of CFC syndrome</article-title>
<source/>Clin Genet
          <year>1997</year>
<volume>52</volume>
<fpage>37</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.1997.tb02512.x</pub-id>
<pub-id pub-id-type="pmid">9272711</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roberts</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Allanson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jadico</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Kavamura</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Noonan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Opitz</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Neri</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The cardiofaciocutaneous syndrome</article-title>
<source/>J Med Genet
          <year>2006</year>
<volume>43</volume>
<fpage>833</fpage>
<lpage>842</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2006.042796</pub-id>
<pub-id pub-id-type="pmid">16825433</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulz</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Albrecht</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Arici</surname>
<given-names>C</given-names>
</name>
<name>
<surname>van der Burgt</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Buske</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gillessen-Kaesbach</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Horn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hubner</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Korenke</surname>
<given-names>GC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome</article-title>
<source/>Clin Genet
          <year>2008</year>
<volume>73</volume>
<fpage>62</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2007.00931.x</pub-id>
<pub-id pub-id-type="pmid">18042262</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Niihori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kawame</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kurosawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ohashi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Filocamo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kure</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Germline mutations in HRAS proto-oncogene cause Costello syndrome</article-title>
<source/>Nat Genet
          <year>2005</year>
<volume>37</volume>
<fpage>1038</fpage>
<lpage>1040</lpage>
<pub-id pub-id-type="doi">10.1038/ng1641</pub-id>
<pub-id pub-id-type="pmid">16170316</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerr</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Delrue</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Sigaudy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Perveen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Marche</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Burgelin</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Stef</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Eden</surname>
<given-names>OB</given-names>
</name>
<name>
<surname>O'Sullivan</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases</article-title>
<source/>J Med Genet
          <year>2006</year>
<volume>43</volume>
<fpage>401</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2005.040352</pub-id>
<pub-id pub-id-type="pmid">16443854</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Estep</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Tidyman</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Teitell</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Cotter</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>KA</given-names>
</name>
</person-group>
<article-title>HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy</article-title>
<source/>Am J Med Genet A
          <year>2006</year>
<volume>140</volume>
<fpage>8</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.31078</pub-id>
<pub-id pub-id-type="pmid">16372351</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zenker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lehmann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Barth</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hansmann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Korinthenberg</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kreiss-Nachtsheim</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Meinecke</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Morlot</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations</article-title>
<source/>J Med Genet
          <year>2007</year>
<volume>44</volume>
<fpage>131</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2006.046300</pub-id>
<pub-id pub-id-type="pmid">17056636</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Der Kaloustian</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Moroz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>McIntosh</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Watters</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Blaichman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Costello syndrome</article-title>
<source/>Am J Med Genet
          <year>1991</year>
<volume>41</volume>
<fpage>69</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320410118</pub-id>
<pub-id pub-id-type="pmid">1951465</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zampino</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mastroiacovo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ricci</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zollino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Segni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Martini-Neri</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Neri</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Costello syndrome: further clinical delineation, natural history, genetic definition, and nosology</article-title>
<source/>Am J Med Genet
          <year>1993</year>
<volume>47</volume>
<fpage>176</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320470210</pub-id>
<pub-id pub-id-type="pmid">8213903</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gripp</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>CI</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Nicholson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Figueroa</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>Second case of bladder carcinoma in a patient with Costello syndrome</article-title>
<source/>Am J Med Genet
          <year>2000</year>
<volume>90</volume>
<fpage>256</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(20000131)90:3&lt;256::AID-AJMG16&gt;3.0.CO;2-D</pub-id>
<pub-id pub-id-type="pmid">10678668</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gripp</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>CI</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Nicholson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>McDonald-McGinn</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Ozeran</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Zackai</surname>
<given-names>EH</given-names>
</name>
</person-group>
<article-title>Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol</article-title>
<source/>Am J Med Genet
          <year>2002</year>
<volume>108</volume>
<fpage>80</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.10241</pub-id>
<pub-id pub-id-type="pmid">11857556</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fryns</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Vogels</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Haegeman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eggermont</surname>
<given-names>E</given-names>
</name>
<name>
<surname>van den Berghe</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Costello syndrome: a postnatal growth retardation syndrome with distinct phenotype</article-title>
<source/>Genet Couns
          <year>1994</year>
<volume>5</volume>
<fpage>337</fpage>
<lpage>343</lpage>
<pub-id pub-id-type="pmid">7888135</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Golabi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Norton</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Rosenblatt</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Fries</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Costello syndrome: phenotype, natural history, differential diagnosis, and possible cause</article-title>
<source/>J Pediatr
          <year>1998</year>
<volume>133</volume>
<fpage>441</fpage>
<lpage>448</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-3476(98)70284-7</pub-id>
<pub-id pub-id-type="pmid">9738731</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerr</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Eden</surname>
<given-names>OB</given-names>
</name>
<name>
<surname>Dandamudi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Quarrell</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Emmerson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ladusans</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gerrard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Donnai</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Costello syndrome: two cases with embryonal rhabdomyosarcoma</article-title>
<source/>J Med Genet
          <year>1998</year>
<volume>35</volume>
<fpage>1036</fpage>
<lpage>1039</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.35.12.1036</pub-id>
<pub-id pub-id-type="pmid">9863604</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Eeghen</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>van Gelderen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hennekam</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Costello syndrome: report and review</article-title>
<source/>Am J Med Genet
          <year>1999</year>
<volume>82</volume>
<fpage>187</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19990115)82:2&lt;187::AID-AJMG17&gt;3.0.CO;2-2</pub-id>
<pub-id pub-id-type="pmid">9934987</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Say</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gucsavas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Morgan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>York</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The Costello syndrome</article-title>
<source/>Am J Med Genet
          <year>1993</year>
<volume>47</volume>
<fpage>163</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320470203</pub-id>
<pub-id pub-id-type="pmid">8213897</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delrue</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Chateil</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Arveiler</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lacombe</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Costello syndrome and neurological abnormalities</article-title>
<source/>Am J Med Genet
          <year>2003</year>
<volume>123a</volume>
<fpage>301</fpage>
<lpage>305</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.20330</pub-id>
<pub-id pub-id-type="pmid">14608654</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Chiyo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Otani</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Futagi</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>A Japanese patient with the Costello syndrome</article-title>
<source/>Hum Genet
          <year>1994</year>
<volume>93</volume>
<fpage>605</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="doi">10.1007/BF00202834</pub-id>
<pub-id pub-id-type="pmid">8168845</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lakkis</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Golden</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>O'Shea</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Neurofibromin deficiency in mice causes exencephaly and is a modifier for Splotch neural tube defects</article-title>
<source/>Dev Biol
          <year>1999</year>
<volume>212</volume>
<fpage>80</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1006/dbio.1999.9327</pub-id>
<pub-id pub-id-type="pmid">10419687</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brannan</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Perkins</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Ratner</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nordlund</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Buchberg</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Copeland</surname>
<given-names>NG</given-names>
</name>
</person-group>
<article-title>Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues</article-title>
<source/>Genes Dev
          <year>1994</year>
<volume>8</volume>
<fpage>1019</fpage>
<lpage>1029</lpage>
<pub-id pub-id-type="doi">10.1101/gad.8.9.1019</pub-id>
<pub-id pub-id-type="pmid">7926784</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacks</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Bernards</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Tumour predisposition in mice heterozygous for a targeted mutation in Nf1</article-title>
<source/>Nat Genet
          <year>1994</year>
<volume>7</volume>
<fpage>353</fpage>
<lpage>361</lpage>
<pub-id pub-id-type="doi">10.1038/ng0794-353</pub-id>
<pub-id pub-id-type="pmid">7920653</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Loehr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Henkemeyer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cashen</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation</article-title>
<source/>Oncogene.
          <year>1999</year>
<volume>18</volume>
<fpage>4450</fpage>
<lpage>4459</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1202829</pub-id>
<pub-id pub-id-type="pmid">10442636</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizvi</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Akunuru</surname>
<given-names>S</given-names>
</name>
<name>
<surname>de Courten-Myers</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Switzer</surname>
<given-names>RC</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Nordlund</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Ratner</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Region-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 (Nf1) tumor suppressor</article-title>
<source/>Brain Res
          <year>1999</year>
<volume>816</volume>
<fpage>111</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(98)01133-0</pub-id>
<pub-id pub-id-type="pmid">9878702</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costa</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Federov</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Kogan</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kucherlapati</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jacks</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1</article-title>
<source/>Nature.
          <year>2002</year>
<volume>415</volume>
<fpage>526</fpage>
<lpage>530</lpage>
<pub-id pub-id-type="doi">10.1038/nature711</pub-id>
<pub-id pub-id-type="pmid">11793011</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Frankland</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Marowitz</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Laszlo</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Cioffi</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jacks</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bourtchuladze</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>A mouse model for the learning and memory deficits associated with neurofibromatosis type I</article-title>
<source/>Nat Genet
          <year>1997</year>
<volume>15</volume>
<fpage>281</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="doi">10.1038/ng0397-281</pub-id>
<pub-id pub-id-type="pmid">9054942</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costa</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Huynh</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Pulst</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Viskochil</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Brannan</surname>
<given-names>CI</given-names>
</name>
</person-group>
<article-title>Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1</article-title>
<source/>Nat Genet
          <year>2001</year>
<volume>27</volume>
<fpage>399</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.1038/86898</pub-id>
<pub-id pub-id-type="pmid">11279521</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Romero</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Charnay</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rushing</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Marth</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>LF</given-names>
</name>
</person-group>
<article-title>Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain</article-title>
<source/>Genes Dev
          <year>2001</year>
<volume>15</volume>
<fpage>859</fpage>
<lpage>876</lpage>
<pub-id pub-id-type="doi">10.1101/gad.862101</pub-id>
<pub-id pub-id-type="pmid">11297510</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Elgersma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Mody</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Neurofibromin regulation of ERK signaling modulates GABA release and learning</article-title>
<source/>Cell.
          <year>2008</year>
<volume>135</volume>
<fpage>549</fpage>
<lpage>560</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2008.09.060</pub-id>
<pub-id pub-id-type="pmid">18984165</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Novitch</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities</article-title>
<source/>Cell.
          <year>2012</year>
<volume>150</volume>
<fpage>816</fpage>
<lpage>830</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2012.06.034</pub-id>
<pub-id pub-id-type="pmid">22901811</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lush</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Guignard</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Bajenaru</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>LF</given-names>
</name>
</person-group>
<article-title>Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation</article-title>
<source/>Development
          <year>2005</year>
<volume>132</volume>
<fpage>5577</fpage>
<lpage>5588</lpage>
<pub-id pub-id-type="doi">10.1242/dev.02162</pub-id>
<pub-id pub-id-type="pmid">16314489</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lush</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>LF</given-names>
</name>
</person-group>
<article-title>Neurofibromin is required for barrel formation in the mouse somatosensory cortex</article-title>
<source/>J Neurosci
          <year>2008</year>
<volume>28</volume>
<fpage>1580</fpage>
<lpage>1587</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5236-07.2008</pub-id>
<pub-id pub-id-type="pmid">18272679</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Ortiz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Nazarenko</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>LF</given-names>
</name>
</person-group>
<article-title>NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development</article-title>
<source/>Genes Dev
          <year>2014</year>
<volume>28</volume>
<fpage>2407</fpage>
<lpage>2420</lpage>
<pub-id pub-id-type="doi">10.1101/gad.246603.114</pub-id>
<pub-id pub-id-type="pmid">25367036</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hegedus</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dasgupta</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Emnett</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hart-Mahon</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Elghazi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bernal-Mizrachi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms</article-title>
<source/>Cell Stem Cell
          <year>2007</year>
<volume>1</volume>
<fpage>443</fpage>
<lpage>457</lpage>
<pub-id pub-id-type="doi">10.1016/j.stem.2007.07.008</pub-id>
<pub-id pub-id-type="pmid">18371380</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bonaguidi</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Stein-O'Brien</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kawasaki</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Modak</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ming</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Latent tri-lineage potential of adult hippocampal neural stem cells revealed by Nf1 inactivation</article-title>
<source/>Nat Neurosci
          <year>2015</year>
<volume>18</volume>
<fpage>1722</fpage>
<lpage>1724</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4159</pub-id>
<pub-id pub-id-type="pmid">26523645</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>McKay</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Riethmacher</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Parada</surname>
<given-names>LF</given-names>
</name>
</person-group>
<article-title>Neurofibromin modulates adult hippocampal neurogenesis and behavioral effects of antidepressants</article-title>
<source/>J Neurosci
          <year>2012</year>
<volume>32</volume>
<fpage>3529</fpage>
<lpage>3539</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3469-11.2012</pub-id>
<pub-id pub-id-type="pmid">22399775</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ke</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Hagihara</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Curran</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ranscht</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality</article-title>
<source/>Mol Cell Biol
          <year>2007</year>
<volume>27</volume>
<fpage>6706</fpage>
<lpage>6717</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.01225-07</pub-id>
<pub-id pub-id-type="pmid">17646384</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Control of oligodendrocyte generation and proliferation by Shp2 protein tyrosine phosphatase</article-title>
<source/>Glia.
          <year>2010</year>
<volume>58</volume>
<fpage>1407</fpage>
<lpage>1414</lpage>
<pub-id pub-id-type="doi">10.1002/glia.21016</pub-id>
<pub-id pub-id-type="pmid">20648636</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ehrman</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Nardini</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ehrman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rizvi</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Gulick</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krenz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dasgupta</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ratner</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nakafuku</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The protein tyrosine phosphatase Shp2 is required for the generation of oligodendrocyte progenitor cells and myelination in the mouse telencephalon</article-title>
<source/>J Neurosci
          <year>2014</year>
<volume>34</volume>
<fpage>3767</fpage>
<lpage>3778</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3515-13.2014</pub-id>
<pub-id pub-id-type="pmid">24599474</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>Hong</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Wen-Mei</given-names>
</name>
<name>
<surname>Waclaw</surname>
<given-names>Ronald R.</given-names>
</name>
<name>
<surname>Kontaridis</surname>
<given-names>Maria I.</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>Benjamin G.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>Cheng-Kui</given-names>
</name>
</person-group>
<article-title>Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner</article-title>
<source/>Science Signaling
          <year>2018</year>
<volume>11</volume>
<issue>522</issue>
<fpage>eaao1591</fpage>
<pub-id pub-id-type="doi">10.1126/scisignal.aao1591</pub-id>
<pub-id pub-id-type="pmid">29559584</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gauthier</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Furstoss</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>FD</given-names>
</name>
</person-group>
<article-title>Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome</article-title>
<source/>Neuron.
          <year>2007</year>
<volume>54</volume>
<fpage>245</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2007.03.027</pub-id>
<pub-id pub-id-type="pmid">17442246</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Ehninger</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kwak</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Butz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome</article-title>
<source/>Nat Neurosci
          <year>2014</year>
<volume>17</volume>
<fpage>1736</fpage>
<lpage>1743</lpage>
<pub-id pub-id-type="doi">10.1038/nn.3863</pub-id>
<pub-id pub-id-type="pmid">25383899</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Araki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mohi</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Ismat</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>IR</given-names>
</name>
<name>
<surname>Kutok</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pao</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Gilliland</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Epstein</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation</article-title>
<source/>Nat Med
          <year>2004</year>
<volume>10</volume>
<fpage>849</fpage>
<lpage>857</lpage>
<pub-id pub-id-type="doi">10.1038/nm1084</pub-id>
<pub-id pub-id-type="pmid">15273746</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papale</surname>
<given-names>Alessandro</given-names>
</name>
<name>
<surname>d’Isa</surname>
<given-names>Raffaele</given-names>
</name>
<name>
<surname>Menna</surname>
<given-names>Elisabetta</given-names>
</name>
<name>
<surname>Cerovic</surname>
<given-names>Milica</given-names>
</name>
<name>
<surname>Solari</surname>
<given-names>Nicola</given-names>
</name>
<name>
<surname>Hardingham</surname>
<given-names>Neil</given-names>
</name>
<name>
<surname>Cambiaghi</surname>
<given-names>Marco</given-names>
</name>
<name>
<surname>Cursi</surname>
<given-names>Marco</given-names>
</name>
<name>
<surname>Barbacid</surname>
<given-names>Mariano</given-names>
</name>
<name>
<surname>Leocani</surname>
<given-names>Letizia</given-names>
</name>
<name>
<surname>Fasano</surname>
<given-names>Stefania</given-names>
</name>
<name>
<surname>Matteoli</surname>
<given-names>Michela</given-names>
</name>
<name>
<surname>Brambilla</surname>
<given-names>Riccardo</given-names>
</name>
</person-group>
<article-title>Severe Intellectual Disability and Enhanced Gamma-Aminobutyric Acidergic Synaptogenesis in a Novel Model of Rare RASopathies</article-title>
<source/>Biological Psychiatry
          <year>2017</year>
<volume>81</volume>
<issue>3</issue>
<fpage>179</fpage>
<lpage>192</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2016.06.016</pub-id>
<pub-id pub-id-type="pmid">27587266</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schreiber</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grimbergen</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Overwater</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Vaart</surname>
<given-names>TV</given-names>
</name>
<name>
<surname>Stedehouder</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schuhmacher</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kushner</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Jaarsma</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Elgersma</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Mechanisms underlying cognitive deficits in a mouse model for Costello Syndrome are distinct from other RASopathy mouse models</article-title>
<source/>Sci Rep
          <year>2017</year>
<volume>7</volume>
<fpage>1256</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-01218-0</pub-id>
<pub-id pub-id-type="pmid">28455524</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kushner</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Elgersma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Jaarsma</surname>
<given-names>D</given-names>
</name>
<name>
<surname>van Woerden</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Hojjati</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>LeBoutillier</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Marrone</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>ES</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Modulation of presynaptic plasticity and learning by the H-ras/extracellular signal-regulated kinase/synapsin I signaling pathway</article-title>
<source/>J Neurosci
          <year>2005</year>
<volume>25</volume>
<fpage>9721</fpage>
<lpage>9734</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2836-05.2005</pub-id>
<pub-id pub-id-type="pmid">16237176</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfeiffer</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gotz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Camarero</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Blum</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Heinsen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nieswandt</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rapp</surname>
<given-names>UR</given-names>
</name>
</person-group>
<article-title>Ablation of BRaf impairs neuronal differentiation in the postnatal hippocampus and cerebellum</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e58259</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0058259</pub-id>
<pub-id pub-id-type="pmid">23505473</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galabova-Kovacs</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Catalanotti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Matzen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Reyes</surname>
<given-names>GX</given-names>
</name>
<name>
<surname>Zezula</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Herbst</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Baccarini</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development</article-title>
<source/>J Cell Biol
          <year>2008</year>
<volume>180</volume>
<fpage>947</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.200709069</pub-id>
<pub-id pub-id-type="pmid">18332218</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urosevic</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sauzeau</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Soto-Montenegro</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Reig</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Desco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Canamero</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mulero</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ortega</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bustelo</surname>
<given-names>XR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2011</year>
<volume>108</volume>
<fpage>5015</fpage>
<lpage>5020</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1016933108</pub-id>
<pub-id pub-id-type="pmid">21383153</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfeiffer</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gotz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Camarero</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Heinsen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Blum</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rapp</surname>
<given-names>UR</given-names>
</name>
</person-group>
<article-title>Impaired neuronal maturation of hippocampal neural progenitor cells in mice lacking CRAF</article-title>
<source/>PLoS One
          <year>2018</year>
<volume>13</volume>
<fpage>e0192067</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0192067</pub-id>
<pub-id pub-id-type="pmid">29590115</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Preiss</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hentze</surname>
<given-names>MW</given-names>
</name>
</person-group>
<article-title>From factors to mechanisms: translation and translational control in eukaryotes</article-title>
<source/>Curr Opin Genet Dev
          <year>1999</year>
<volume>9</volume>
<fpage>515</fpage>
<lpage>521</lpage>
<pub-id pub-id-type="doi">10.1016/S0959-437X(99)00005-2</pub-id>
<pub-id pub-id-type="pmid">10508691</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holter</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Hewitt</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Koebele</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Judd</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bimonte-Nelson</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Conrad</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Snider</surname>
<given-names>WD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Noonan Syndrome-linked Raf1L613V mutation drives increased glial number in the mouse cortex and enhanced learning</article-title>
<source/>PLoS Genet
          <year>2019</year>
<volume>15</volume>
<fpage>e1008108</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1008108</pub-id>
<pub-id pub-id-type="pmid">31017896</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoidi</surname>
<given-names>Rifdat</given-names>
</name>
<name>
<surname>Houde</surname>
<given-names>Nicolas</given-names>
</name>
<name>
<surname>Landry-Truchon</surname>
<given-names>Kim</given-names>
</name>
<name>
<surname>Holter</surname>
<given-names>Michael</given-names>
</name>
<name>
<surname>Jacquet</surname>
<given-names>Kevin</given-names>
</name>
<name>
<surname>Charron</surname>
<given-names>Louis</given-names>
</name>
<name>
<surname>Krishnaswami</surname>
<given-names>Suguna Rani</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Benjamin D.</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>Katherine A.</given-names>
</name>
<name>
<surname>Bisson</surname>
<given-names>Nicolas</given-names>
</name>
<name>
<surname>Newbern</surname>
<given-names>Jason</given-names>
</name>
<name>
<surname>Charron</surname>
<given-names>Jean</given-names>
</name>
</person-group>
<article-title>Mek1Y130Cmice recapitulate aspects of human cardio-facio-cutaneous syndrome</article-title>
<source/>Disease Models &amp; Mechanisms
          <year>2018</year>
<volume>11</volume>
<issue>3</issue>
<fpage>dmm031278</fpage>
<pub-id pub-id-type="doi">10.1242/dmm.031278</pub-id>
<pub-id pub-id-type="pmid">29590634</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Newbern</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Morgan-Smith</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Charron</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Snider</surname>
<given-names>WD</given-names>
</name>
</person-group>
<article-title>MEK Is a Key Regulator of Gliogenesis in the Developing Brain</article-title>
<source/>Neuron.
          <year>2012</year>
<volume>75</volume>
<fpage>1035</fpage>
<lpage>1050</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.08.031</pub-id>
<pub-id pub-id-type="pmid">22998872</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ivanova</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Karolczak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Beyer</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Estrogen stimulates the mitogen-activated protein kinase pathway in midbrain astroglia</article-title>
<source/>Brain Res
          <year>2001</year>
<volume>889</volume>
<fpage>264</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-8993(00)03149-8</pub-id>
<pub-id pub-id-type="pmid">11166717</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campos</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Leone</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Relvas</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Brakebusch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fassler</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Suter</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>ffrench-Constant C. Beta1 integrins activate a MAPK signalling pathway in neural stem cells that contributes to their maintenance</article-title>
<source/>Development
          <year>2004</year>
<volume>131</volume>
<fpage>3433</fpage>
<lpage>3444</lpage>
<pub-id pub-id-type="doi">10.1242/dev.01199</pub-id>
<pub-id pub-id-type="pmid">15226259</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brunet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>West</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Datta</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Takasu</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms</article-title>
<source/>Science
          <year>1999</year>
<volume>286</volume>
<fpage>1358</fpage>
<lpage>1362</lpage>
<pub-id pub-id-type="doi">10.1126/science.286.5443.1358</pub-id>
<pub-id pub-id-type="pmid">10558990</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Dickens</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Raingeaud</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis</article-title>
<source/>Science.
          <year>1995</year>
<volume>270</volume>
<fpage>1326</fpage>
<lpage>1331</lpage>
<pub-id pub-id-type="doi">10.1126/science.270.5240.1326</pub-id>
<pub-id pub-id-type="pmid">7481820</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michaelidis</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Sendtner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Airaksinen</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Holtmann</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thoenen</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Inactivation of bcl-2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development</article-title>
<source/>Neuron.
          <year>1996</year>
<volume>17</volume>
<fpage>75</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(00)80282-2</pub-id>
<pub-id pub-id-type="pmid">8755480</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krasilnikov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ivanov</surname>
<given-names>VN</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ronai</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis</article-title>
<source/>Oncogene.
          <year>2003</year>
<volume>22</volume>
<fpage>4092</fpage>
<lpage>4101</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1206598</pub-id>
<pub-id pub-id-type="pmid">12821943</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulich</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>CT</given-names>
</name>
</person-group>
<article-title>Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease</article-title>
<source/>J Neurochem
          <year>2001</year>
<volume>77</volume>
<fpage>1058</fpage>
<lpage>1066</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00304.x</pub-id>
<pub-id pub-id-type="pmid">11359871</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dolcini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Salis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Venezia</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Violani</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Carlo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zambrano</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schettini</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Signal transduction through tyrosine-phosphorylated carboxy-terminal fragments of APP via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain</article-title>
<source/>Ann N Y Acad Sci
          <year>2002</year>
<volume>973</volume>
<fpage>323</fpage>
<lpage>333</lpage>
<pub-id pub-id-type="doi">10.1111/j.1749-6632.2002.tb04660.x</pub-id>
<pub-id pub-id-type="pmid">12485888</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pucilowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Puzerey</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Karlo</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Galan</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Landreth</surname>
<given-names>GE</given-names>
</name>
</person-group>
<article-title>Disrupted ERK signaling during cortical development leads to abnormal progenitor proliferation, neuronal and network excitability and behavior, modeling human neuro-cardio-facial-cutaneous and related syndromes</article-title>
<source/>J Neurosci
          <year>2012</year>
<volume>32</volume>
<fpage>8663</fpage>
<lpage>8677</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1107-12.2012</pub-id>
<pub-id pub-id-type="pmid">22723706</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hein</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Paquin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Savelson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>XM</given-names>
</name>
<name>
<surname>Lederfein</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Barnabe-Heider</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mir</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Sterneck</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>AC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An essential role for a MEK-C/EBP pathway during growth factor-regulated cortical neurogenesis</article-title>
<source/>Neuron.
          <year>2002</year>
<volume>36</volume>
<fpage>597</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="doi">10.1016/S0896-6273(02)01026-7</pub-id>
<pub-id pub-id-type="pmid">12441050</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>FGF2-induced chromatin remodeling regulates CNTF-mediated gene expression and astrocyte differentiation</article-title>
<source/>Nat Neurosci
          <year>2004</year>
<volume>7</volume>
<fpage>229</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1038/nn1192</pub-id>
<pub-id pub-id-type="pmid">14770186</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrow</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Sequential specification of neurons and glia by developmentally regulated extracellular factors</article-title>
<source/>Development
          <year>2001</year>
<volume>128</volume>
<fpage>3585</fpage>
<lpage>3594</lpage>
<pub-id pub-id-type="pmid">11566862</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bajetto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barbero</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bonavia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Piccioli</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pirani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Florio</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schettini</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Stromal cell-derived factor-1alpha induces astrocyte proliferation through the activation of extracellular signal-regulated kinases 1/2 pathway</article-title>
<source/>J Neurochem
          <year>2001</year>
<volume>77</volume>
<fpage>1226</fpage>
<lpage>1236</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00350.x</pub-id>
<pub-id pub-id-type="pmid">11389173</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baron</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Metz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bansal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hoekstra</surname>
<given-names>D</given-names>
</name>
<name>
<surname>de Vries</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>PDGF and FGF-2 signaling in oligodendrocyte progenitor cells: regulation of proliferation and differentiation by multiple intracellular signaling pathways</article-title>
<source/>Mol Cell Neurosci
          <year>2000</year>
<volume>15</volume>
<fpage>314</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="doi">10.1006/mcne.1999.0827</pub-id>
<pub-id pub-id-type="pmid">10736207</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guardiola-Diaz</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bansal</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Erk1/2 MAPK and mTOR signaling sequentially regulates progression through distinct stages of oligodendrocyte differentiation</article-title>
<source/>Glia.
          <year>2012</year>
<volume>60</volume>
<fpage>476</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22281</pub-id>
<pub-id pub-id-type="pmid">22144101</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fyffe-Maricich</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Karlo</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Landreth</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation</article-title>
<source/>J Neurosci
          <year>2011</year>
<volume>31</volume>
<fpage>843</fpage>
<lpage>850</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3239-10.2011</pub-id>
<pub-id pub-id-type="pmid">21248107</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ferner</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Denham</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kilpatrick</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>SS</given-names>
</name>
</person-group>
<article-title>Extracellular signal-regulated kinase 1/2 signaling promotes oligodendrocyte myelination in vitro</article-title>
<source/>J Neurochem
          <year>2012</year>
<volume>122</volume>
<fpage>1167</fpage>
<lpage>1180</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2012.07871.x</pub-id>
<pub-id pub-id-type="pmid">22784206</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Suo</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>YE</given-names>
</name>
<name>
<surname>He</surname>
<given-names>B</given-names>
</name>
</person-group>
<source/>Gu H, Xie X
          <year>2019</year>
<publisher-loc>Glia</publisher-loc>
<publisher-name>Inhibition of MAPK/ERK pathway promotes oligodendrocytes generation and recovery of demyelinating diseases</publisher-name>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fressinaud</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vallat</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Labourdette</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Basic fibroblast growth factor down-regulates myelin basic protein gene expression and alters myelin compaction of mature oligodendrocytes in vitro</article-title>
<source/>J Neurosci Res
          <year>1995</year>
<volume>40</volume>
<fpage>285</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.490400302</pub-id>
<pub-id pub-id-type="pmid">7745622</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bansal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pfeiffer</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>FGF-2 converts mature oligodendrocytes to a novel phenotype</article-title>
<source/>J Neurosci Res
          <year>1997</year>
<volume>50</volume>
<fpage>215</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1097-4547(19971015)50:2&lt;215::AID-JNR10&gt;3.0.CO;2-7</pub-id>
<pub-id pub-id-type="pmid">9373031</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canoll</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Kraemer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Marchionni</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Salzer</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>GGF/neuregulin induces a phenotypic reversion of oligodendrocytes</article-title>
<source/>Mol Cell Neurosci
          <year>1999</year>
<volume>13</volume>
<fpage>79</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1006/mcne.1998.0733</pub-id>
<pub-id pub-id-type="pmid">10192767</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casarosa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fode</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Guillemot</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Mash1 regulates neurogenesis in the ventral telencephalon</article-title>
<source/>Development
          <year>1999</year>
<volume>126</volume>
<fpage>525</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="pmid">9876181</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Britz</surname>
<given-names>Olivier</given-names>
</name>
<name>
<surname>Mattar</surname>
<given-names>Pierre</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>Laurent</given-names>
</name>
<name>
<surname>Langevin</surname>
<given-names>Lisa-Marie</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>Céline</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>Sharmila</given-names>
</name>
<name>
<surname>Guillemot</surname>
<given-names>François</given-names>
</name>
<name>
<surname>Schuurmans</surname>
<given-names>Carol</given-names>
</name>
</person-group>
<article-title>A Role for Proneural Genes in the Maturation of Cortical Progenitor Cells</article-title>
<source/>Cerebral Cortex
          <year>2006</year>
<volume>16</volume>
<issue>suppl_1</issue>
<fpage>i138</fpage>
<lpage>i151</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bhj168</pub-id>
<pub-id pub-id-type="pmid">16766700</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parras</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sugimori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nakafuku</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rowitch</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Guillemot</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>The proneural gene Mash1 specifies an early population of telencephalic oligodendrocytes</article-title>
<source/>J Neurosci
          <year>2007</year>
<volume>27</volume>
<fpage>4233</fpage>
<lpage>4242</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0126-07.2007</pub-id>
<pub-id pub-id-type="pmid">17442807</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mattar</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dixit</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lawn</surname>
<given-names>SO</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kinch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Eisenstat</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kurrasch</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Schuurmans</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>RAS/ERK signaling controls proneural genetic programs in cortical development and gliomagenesis</article-title>
<source/>J Neurosci
          <year>2014</year>
<volume>34</volume>
<fpage>2169</fpage>
<lpage>2190</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4077-13.2014</pub-id>
<pub-id pub-id-type="pmid">24501358</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vivanco</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Sawyers</surname>
<given-names>CL</given-names>
</name>
</person-group>
<article-title>The phosphatidylinositol 3-Kinase AKT pathway in human cancer</article-title>
<source/>Nat Rev Cancer
          <year>2002</year>
<volume>2</volume>
<fpage>489</fpage>
<lpage>501</lpage>
<pub-id pub-id-type="doi">10.1038/nrc839</pub-id>
<pub-id pub-id-type="pmid">12094235</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castellano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Downward</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Role of RAS in the regulation of PI 3-kinase</article-title>
<source/>Curr Top Microbiol Immunol
          <year>2010</year>
<volume>346</volume>
<fpage>143</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="pmid">20563706</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Downward</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Targeting RAS signalling pathways in cancer therapy</article-title>
<source/>Nat Rev Cancer
          <year>2003</year>
<volume>3</volume>
<fpage>11</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1038/nrc969</pub-id>
<pub-id pub-id-type="pmid">12509763</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendoza</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Er</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Blenis</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation</article-title>
<source/>Trends Biochem Sci
          <year>2011</year>
<volume>36</volume>
<fpage>320</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="doi">10.1016/j.tibs.2011.03.006</pub-id>
<pub-id pub-id-type="pmid">21531565</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Sim</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Kwak</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PI3Kgamma is required for NMDA receptor-dependent long-term depression and behavioral flexibility</article-title>
<source/>Nat Neurosci
          <year>2011</year>
<volume>14</volume>
<fpage>1447</fpage>
<lpage>1454</lpage>
<pub-id pub-id-type="doi">10.1038/nn.2937</pub-id>
<pub-id pub-id-type="pmid">22019731</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Baek</surname>
<given-names>GC</given-names>
</name>
<name>
<surname>Sim</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Collingridge</surname>
<given-names>GL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of PI3Kgamma overexpression in the hippocampus on synaptic plasticity and spatial learning</article-title>
<source/>Mol Brain
          <year>2014</year>
<volume>7</volume>
<fpage>78</fpage>
<pub-id pub-id-type="doi">10.1186/s13041-014-0078-6</pub-id>
<pub-id pub-id-type="pmid">25373491</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rawlings</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Rosler</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>The JAK/STAT signaling pathway</article-title>
<source/>J Cell Sci
          <year>2004</year>
<volume>117</volume>
<fpage>1281</fpage>
<lpage>1283</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.00963</pub-id>
<pub-id pub-id-type="pmid">15020666</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolas</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Peineau</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Amici</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Csaba</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fafouri</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Javalet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Collett</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Hildebrandt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Seaton</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>SL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Jak/STAT pathway is involved in synaptic plasticity</article-title>
<source/>Neuron.
          <year>2012</year>
<volume>73</volume>
<fpage>374</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2011.11.024</pub-id>
<pub-id pub-id-type="pmid">22284190</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krab</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Goorden</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Elgersma</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases</article-title>
<source/>Trends Genet
          <year>2008</year>
<volume>24</volume>
<fpage>498</fpage>
<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1016/j.tig.2008.07.005</pub-id>
<pub-id pub-id-type="pmid">18774199</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bentires-Alj</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kontaridis</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>Stops along the RAS pathway in human genetic disease</article-title>
<source/>Nat Med
          <year>2006</year>
<volume>12</volume>
<fpage>283</fpage>
<lpage>285</lpage>
<pub-id pub-id-type="doi">10.1038/nm0306-283</pub-id>
<pub-id pub-id-type="pmid">16520774</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cawthon</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Viskochil</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Culver</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gesteland</surname>
<given-names>R</given-names>
</name>
<name>
<surname>O'Connell</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations</article-title>
<source/>Cell.
          <year>1990</year>
<volume>62</volume>
<fpage>193</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(90)90253-B</pub-id>
<pub-id pub-id-type="pmid">2114220</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Viskochil</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bollag</surname>
<given-names>G</given-names>
</name>
<name>
<surname>McCabe</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Crosier</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Haubruck</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Conroy</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>R</given-names>
</name>
<name>
<surname>O'Connell</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cawthon</surname>
<given-names>RM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21</article-title>
<source/>Cell.
          <year>1990</year>
<volume>63</volume>
<fpage>843</fpage>
<lpage>849</lpage>
<pub-id pub-id-type="doi">10.1016/0092-8674(90)90150-D</pub-id>
<pub-id pub-id-type="pmid">2121370</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Aylsworth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pyeritz</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Rubenstein</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Viskochil</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2</article-title>
<source/>Jama.
          <year>1997</year>
<volume>278</volume>
<fpage>51</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1001/jama.1997.03550010065042</pub-id>
<pub-id pub-id-type="pmid">9207339</pub-id>
</element-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Listernick</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Charrow</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Intracranial gliomas in neurofibromatosis type 1</article-title>
<source/>Am J Med Genet
          <year>1999</year>
<volume>89</volume>
<fpage>38</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19990326)89:1&lt;38::AID-AJMG8&gt;3.0.CO;2-M</pub-id>
<pub-id pub-id-type="pmid">10469435</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nordlund</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Rizvi</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Brannan</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Ratner</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Neurofibromin expression and astrogliosis in neurofibromatosis (type 1) brains</article-title>
<source/>J Neuropathol Exp Neurol
          <year>1995</year>
<volume>54</volume>
<fpage>588</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="doi">10.1097/00005072-199507000-00013</pub-id>
<pub-id pub-id-type="pmid">7602332</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname>
<given-names>BD</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Slopis</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>De Winter</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Leeds</surname>
<given-names>NE</given-names>
</name>
</person-group>
<article-title>Brain volume in children with neurofibromatosis type 1: relation to neuropsychological status</article-title>
<source/>Neurology.
          <year>2000</year>
<volume>54</volume>
<fpage>914</fpage>
<lpage>920</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.54.4.914</pub-id>
<pub-id pub-id-type="pmid">10690986</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pride</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Payne</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shores</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Rae</surname>
<given-names>C</given-names>
</name>
<name>
<surname>North</surname>
<given-names>KN</given-names>
</name>
</person-group>
<article-title>Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1</article-title>
<source/>J Child Neurol
          <year>2010</year>
<volume>25</volume>
<fpage>834</fpage>
<lpage>841</lpage>
<pub-id pub-id-type="doi">10.1177/0883073809350723</pub-id>
<pub-id pub-id-type="pmid">20142468</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costa</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1</article-title>
<source/>J Child Neurol
          <year>2002</year>
<volume>17</volume>
<fpage>622</fpage>
<lpage>626</lpage>
<pub-id pub-id-type="doi">10.1177/088307380201700813</pub-id>
<pub-id pub-id-type="pmid">12403561</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kushner</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Jentsch</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Frankland</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1</article-title>
<source/>Curr Biol
          <year>2005</year>
<volume>15</volume>
<fpage>1961</fpage>
<lpage>1967</lpage>
<pub-id pub-id-type="doi">10.1016/j.cub.2005.09.043</pub-id>
<pub-id pub-id-type="pmid">16271875</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Acosta</surname>
<given-names>MT</given-names>
</name>
</person-group>
<article-title>Challenges of cognitive research in neurofibromatosis type 1</article-title>
<source/>Lancet Neurol
          <year>2013</year>
<volume>12</volume>
<fpage>1040</fpage>
<lpage>1041</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(13)70179-0</pub-id>
<pub-id pub-id-type="pmid">24107290</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabchevsky</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Weinitz</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Coulpier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fages</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tinel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Junier</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>A role for transforming growth factor alpha as an inducer of astrogliosis</article-title>
<source/>J Neurosci
          <year>1998</year>
<volume>18</volume>
<fpage>10541</fpage>
<lpage>10552</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.18-24-10541.1998</pub-id>
<pub-id pub-id-type="pmid">9852591</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhuo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Theis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alvarez-Maya</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Brenner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Willecke</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Messing</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo</article-title>
<source/>Genesis
          <year>2001</year>
<volume>31</volume>
<fpage>85</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1002/gene.10008</pub-id>
<pub-id pub-id-type="pmid">11668683</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bennett</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Rizvi</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Karyala</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McKinnon</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Ratner</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Aberrant growth and differentiation of oligodendrocyte progenitors in neurofibromatosis type 1 mutants</article-title>
<source/>J Neurosci
          <year>2003</year>
<volume>23</volume>
<fpage>7207</fpage>
<lpage>7217</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-18-07207.2003</pub-id>
<pub-id pub-id-type="pmid">12904481</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ratner</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase</article-title>
<source/>Mol Cell Biol
          <year>1997</year>
<volume>17</volume>
<fpage>862</fpage>
<lpage>872</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.17.2.862</pub-id>
<pub-id pub-id-type="pmid">9001241</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dasgupta</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo</article-title>
<source/>J Neurosci
          <year>2005</year>
<volume>25</volume>
<fpage>5584</fpage>
<lpage>5594</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4693-04.2005</pub-id>
<pub-id pub-id-type="pmid">15944386</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Emnett</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>White</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner</article-title>
<source/>Genes Dev
          <year>2010</year>
<volume>24</volume>
<fpage>2317</fpage>
<lpage>2329</lpage>
<pub-id pub-id-type="doi">10.1101/gad.1957110</pub-id>
<pub-id pub-id-type="pmid">20876733</pub-id>
</element-citation>
</ref>
<ref id="CR161">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification</article-title>
<source/>Cell.
          <year>2002</year>
<volume>109</volume>
<fpage>61</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(02)00677-3</pub-id>
<pub-id pub-id-type="pmid">11955447</pub-id>
</element-citation>
</ref>
<ref id="CR162">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryu</surname>
<given-names>Hyun-Hee</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>TaeHyun</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Jung-Woong</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>Minkyung</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Pojeong</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Yong Gyu</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Hyopil</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>Jiyeon</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>Ja Eun</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Jisu</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>Chae-Seok</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Chul-Hong</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Sang Jeong</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>Alcino J.</given-names>
</name>
<name>
<surname>Kaang</surname>
<given-names>Bong-Kiun</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Yong-Seok</given-names>
</name>
</person-group>
<article-title>Excitatory neuron–specific SHP2-ERK signaling network regulates synaptic plasticity and memory</article-title>
<source/>Science Signaling
          <year>2019</year>
<volume>12</volume>
<issue>571</issue>
<fpage>eaau5755</fpage>
<pub-id pub-id-type="doi">10.1126/scisignal.aau5755</pub-id>
<pub-id pub-id-type="pmid">30837304</pub-id>
</element-citation>
</ref>
<ref id="CR163">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryu</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YS</given-names>
</name>
</person-group>
<article-title>Enriched expression of NF1 in inhibitory neurons in both mouse and human brain</article-title>
<source/>Mol Brain
          <year>2019</year>
<volume>12</volume>
<fpage>60</fpage>
<pub-id pub-id-type="doi">10.1186/s13041-019-0481-0</pub-id>
<pub-id pub-id-type="pmid">31234911</pub-id>
</element-citation>
</ref>
<ref id="CR164">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tartaglia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gelb</surname>
<given-names>BD</given-names>
</name>
</person-group>
<article-title>Noonan syndrome and related disorders: genetics and pathogenesis</article-title>
<source/>Annu Rev Genomics Hum Genet
          <year>2005</year>
<volume>6</volume>
<fpage>45</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.genom.6.080604.162305</pub-id>
<pub-id pub-id-type="pmid">16124853</pub-id>
</element-citation>
</ref>
<ref id="CR165">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romano</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Allanson</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Dahlgren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gelb</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pierpont</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Takemoto</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Noonan</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Noonan syndrome: clinical features, diagnosis, and management guidelines</article-title>
<source/>Pediatrics.
          <year>2010</year>
<volume>126</volume>
<fpage>746</fpage>
<lpage>759</lpage>
<pub-id pub-id-type="doi">10.1542/peds.2009-3207</pub-id>
<pub-id pub-id-type="pmid">20876176</pub-id>
</element-citation>
</ref>
<ref id="CR166">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yung</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Trinh</surname>
<given-names>QM</given-names>
</name>
<name>
<surname>Peltekova</surname>
<given-names>VD</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Tworog-Dube</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Next-generation sequencing identifies rare variants associated with Noonan syndrome</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2014</year>
<volume>111</volume>
<fpage>11473</fpage>
<lpage>11478</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1324128111</pub-id>
<pub-id pub-id-type="pmid">25049390</pub-id>
</element-citation>
</ref>
<ref id="CR167">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tartaglia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mehler</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zampino</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Brunner</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Kremer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>van der Burgt</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Crosby</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Ion</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jeffery</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome</article-title>
<source/>Nat Genet
          <year>2001</year>
<volume>29</volume>
<fpage>465</fpage>
<lpage>468</lpage>
<pub-id pub-id-type="doi">10.1038/ng772</pub-id>
<pub-id pub-id-type="pmid">11704759</pub-id>
</element-citation>
</ref>
<ref id="CR168">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarkozy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Digilio</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Dallapiccola</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Leopard syndrome</article-title>
<source/>Orphanet J Rare Dis
          <year>2008</year>
<volume>3</volume>
<fpage>13</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1172-3-13</pub-id>
<pub-id pub-id-type="pmid">18505544</pub-id>
</element-citation>
</ref>
<ref id="CR169">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Wakimoto</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Conner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Seidman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Seidman</surname>
<given-names>JG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation</article-title>
<source/>J Clin Invest
          <year>2010</year>
<volume>120</volume>
<fpage>4353</fpage>
<lpage>4365</lpage>
<pub-id pub-id-type="doi">10.1172/JCI43910</pub-id>
<pub-id pub-id-type="pmid">21041952</pub-id>
</element-citation>
</ref>
<ref id="CR170">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gulick</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pratt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Robbins</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2009</year>
<volume>106</volume>
<fpage>15436</fpage>
<lpage>15441</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0903302106</pub-id>
<pub-id pub-id-type="pmid">19706403</pub-id>
</element-citation>
</ref>
<ref id="CR171">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hernandez-Porras</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Fabbiano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schuhmacher</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Aicher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Canamero</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Camara</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Cusso</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Desco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heeschen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mulero</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>K-RasV14I recapitulates Noonan syndrome in mice</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2014</year>
<volume>111</volume>
<fpage>16395</fpage>
<lpage>16400</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1418126111</pub-id>
<pub-id pub-id-type="pmid">25359213</pub-id>
</element-citation>
</ref>
<ref id="CR172">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Thavarajah</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Backx</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Araki</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation</article-title>
<source/>J Clin Invest
          <year>2011</year>
<volume>121</volume>
<fpage>1009</fpage>
<lpage>1025</lpage>
<pub-id pub-id-type="doi">10.1172/JCI44929</pub-id>
<pub-id pub-id-type="pmid">21339642</pub-id>
</element-citation>
</ref>
<ref id="CR173">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Araki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Newbigging</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morikawa</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2009</year>
<volume>106</volume>
<fpage>4736</fpage>
<lpage>4741</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0810053106</pub-id>
<pub-id pub-id-type="pmid">19251646</pub-id>
</element-citation>
</ref>
<ref id="CR174">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meyerson</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>CK</given-names>
</name>
</person-group>
<article-title>Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2016</year>
<volume>113</volume>
<fpage>984</fpage>
<lpage>989</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1508535113</pub-id>
<pub-id pub-id-type="pmid">26755576</pub-id>
</element-citation>
</ref>
<ref id="CR175">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nagai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kanegane</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ohyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Onishi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hanew</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome</article-title>
<source/>J Clin Endocrinol Metab
          <year>2004</year>
<volume>89</volume>
<fpage>3359</fpage>
<lpage>3364</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2003-032091</pub-id>
<pub-id pub-id-type="pmid">15240615</pub-id>
</element-citation>
</ref>
<ref id="CR176">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keilhack</surname>
<given-names>H</given-names>
</name>
<name>
<surname>David</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>McGregor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cantley</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes</article-title>
<source/>J Biol Chem
          <year>2005</year>
<volume>280</volume>
<fpage>30984</fpage>
<lpage>30993</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M504699200</pub-id>
<pub-id pub-id-type="pmid">15987685</pub-id>
</element-citation>
</ref>
<ref id="CR177">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pao</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling</article-title>
<source/>Trends Biochem Sci
          <year>2003</year>
<volume>28</volume>
<fpage>284</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="doi">10.1016/S0968-0004(03)00091-4</pub-id>
<pub-id pub-id-type="pmid">12826400</pub-id>
</element-citation>
</ref>
<ref id="CR178">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ernst</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>BJ</given-names>
</name>
</person-group>
<article-title>Acquiring signalling specificity from the cytokine receptor gp130</article-title>
<source/>Trends Genet
          <year>2004</year>
<volume>20</volume>
<fpage>23</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1016/j.tig.2003.11.003</pub-id>
<pub-id pub-id-type="pmid">14698616</pub-id>
</element-citation>
</ref>
<ref id="CR179">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>GS</given-names>
</name>
</person-group>
<article-title>Shp-2 tyrosine phosphatase: signaling one cell or many</article-title>
<source/>Exp Cell Res
          <year>1999</year>
<volume>253</volume>
<fpage>47</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1006/excr.1999.4668</pub-id>
<pub-id pub-id-type="pmid">10579910</pub-id>
</element-citation>
</ref>
<ref id="CR180">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chong</surname>
<given-names>ZZ</given-names>
</name>
<name>
<surname>Maiese</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury</article-title>
<source/>Histol Histopathol
          <year>2007</year>
<volume>22</volume>
<fpage>1251</fpage>
<lpage>1267</lpage>
<pub-id pub-id-type="pmid">17647198</pub-id>
</element-citation>
</ref>
<ref id="CR181">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marin</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Clemente</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Picardi</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Pascoal</surname>
<given-names>VD</given-names>
</name>
<name>
<surname>Lopes-Cendes</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Saad</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Franchini</surname>
<given-names>KG</given-names>
</name>
</person-group>
<article-title>Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways</article-title>
<source/>Circ Res
          <year>2008</year>
<volume>103</volume>
<fpage>813</fpage>
<lpage>824</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.179754</pub-id>
<pub-id pub-id-type="pmid">18757826</pub-id>
</element-citation>
</ref>
<ref id="CR182">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neel</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>Structure and function of SH2-domain containing tyrosine phosphatases</article-title>
<source/>Semin Cell Biol
          <year>1993</year>
<volume>4</volume>
<fpage>419</fpage>
<lpage>432</lpage>
<pub-id pub-id-type="doi">10.1006/scel.1993.1050</pub-id>
<pub-id pub-id-type="pmid">8305681</pub-id>
</element-citation>
</ref>
<ref id="CR183">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu</surname>
<given-names>CK</given-names>
</name>
</person-group>
<article-title>The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions</article-title>
<source/>Cell Res
          <year>2000</year>
<volume>10</volume>
<fpage>279</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="doi">10.1038/sj.cr.7290055</pub-id>
<pub-id pub-id-type="pmid">11191350</pub-id>
</element-citation>
</ref>
<ref id="CR184">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Temporal requirement of the protein tyrosine phosphatase Shp2 in establishing the neuronal fate in early retinal development</article-title>
<source/>J Neurosci
          <year>2010</year>
<volume>30</volume>
<fpage>4110</fpage>
<lpage>4119</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4364-09.2010</pub-id>
<pub-id pub-id-type="pmid">20237281</pub-id>
</element-citation>
</ref>
<ref id="CR185">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Chueh</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Hueng</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>YF</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>MH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Involvement of SHP2 in focal adhesion, migration and differentiation of neural stem cells</article-title>
<source/>Brain and Development
          <year>2012</year>
<volume>34</volume>
<fpage>674</fpage>
<lpage>684</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2011.10.011</pub-id>
<pub-id pub-id-type="pmid">22118986</pub-id>
</element-citation>
</ref>
<ref id="CR186">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Tzvetanova</surname>
<given-names>ID</given-names>
</name>
<name>
<surname>Leiton</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Colognato</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Tyrosine phosphatases Shp1 and Shp2 have unique and opposing roles in oligodendrocyte development</article-title>
<source/>J Neurochem
          <year>2010</year>
<volume>113</volume>
<fpage>200</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06596.x</pub-id>
<pub-id pub-id-type="pmid">20132481</pub-id>
</element-citation>
</ref>
<ref id="CR187">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>SHP-2 promotes the maturation of oligodendrocyte precursor cells through Akt and ERK1/2 signaling in vitro</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<fpage>e21058</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0021058</pub-id>
<pub-id pub-id-type="pmid">21701583</pub-id>
</element-citation>
</ref>
<ref id="CR188">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grossmann</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Wende</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Cheret</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Garratt</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Zurborg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Feinberg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Besser</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Peles</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The tyrosine phosphatase Shp2 (PTPN11) directs Neuregulin-1/ErbB signaling throughout Schwann cell development</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2009</year>
<volume>106</volume>
<fpage>16704</fpage>
<lpage>16709</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0904336106</pub-id>
<pub-id pub-id-type="pmid">19805360</pub-id>
</element-citation>
</ref>
<ref id="CR189">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anastasaki</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Estep</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Marais</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Patton</surname>
<given-names>EE</given-names>
</name>
</person-group>
<article-title>Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors</article-title>
<source/>Hum Mol Genet
          <year>2009</year>
<volume>18</volume>
<fpage>2543</fpage>
<lpage>2554</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddp186</pub-id>
<pub-id pub-id-type="pmid">19376813</pub-id>
</element-citation>
</ref>
<ref id="CR190">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeh</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Dao</surname>
<given-names>D Q</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z Y</given-names>
</name>
<name>
<surname>Kandalam</surname>
<given-names>S M</given-names>
</name>
<name>
<surname>Camacho</surname>
<given-names>F M</given-names>
</name>
<name>
<surname>Tom</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Krencik</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>K A</given-names>
</name>
<name>
<surname>Ullian</surname>
<given-names>E M</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>L A</given-names>
</name>
</person-group>
<article-title>Patient-derived iPSCs show premature neural differentiation and neuron type-specific phenotypes relevant to neurodevelopment</article-title>
<source/>Molecular Psychiatry
          <year>2017</year>
<volume>23</volume>
<issue>8</issue>
<fpage>1687</fpage>
<lpage>1698</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2017.238</pub-id>
<pub-id pub-id-type="pmid">29158583</pub-id>
</element-citation>
</ref>
<ref id="CR191">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeh</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Gianino</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation</article-title>
<source/>Glia.
          <year>2009</year>
<volume>57</volume>
<fpage>1239</fpage>
<lpage>1249</lpage>
<pub-id pub-id-type="doi">10.1002/glia.20845</pub-id>
<pub-id pub-id-type="pmid">19191334</pub-id>
</element-citation>
</ref>
<ref id="CR192">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moriya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Miyagawa-Tomita</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Oba</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Niihori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ohnishi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kure</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Matsubara</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adult mice expressing a Braf Q241R mutation on an ICR/CD-1 background exhibit a cardio-facio-cutaneous syndrome phenotype</article-title>
<source/>Hum Mol Genet
          <year>2015</year>
<volume>24</volume>
<fpage>7349</fpage>
<lpage>7360</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddv435</pub-id>
<pub-id pub-id-type="pmid">26472072</pub-id>
</element-citation>
</ref>
<ref id="CR193">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiese</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Karch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Troppmair</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Holtmann</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rapp</surname>
<given-names>UR</given-names>
</name>
<name>
<surname>Sendtner</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Specific function of B-Raf in mediating survival of embryonic motoneurons and sensory neurons</article-title>
<source/>Nat Neurosci
          <year>2001</year>
<volume>4</volume>
<fpage>137</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="doi">10.1038/83960</pub-id>
<pub-id pub-id-type="pmid">11175873</pub-id>
</element-citation>
</ref>
<ref id="CR194">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wojnowski</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Hahn</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bernal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rapp</surname>
<given-names>UR</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Endothelial apoptosis in Braf-deficient mice</article-title>
<source/>Nat Genet
          <year>1997</year>
<volume>16</volume>
<fpage>293</fpage>
<lpage>297</lpage>
<pub-id pub-id-type="doi">10.1038/ng0797-293</pub-id>
<pub-id pub-id-type="pmid">9207797</pub-id>
</element-citation>
</ref>
<ref id="CR195">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Giese</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memory</article-title>
<source/>J Neurosci Res
          <year>2006</year>
<volume>83</volume>
<fpage>28</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.20703</pub-id>
<pub-id pub-id-type="pmid">16342120</pub-id>
</element-citation>
</ref>
<ref id="CR196">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andreadi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Giblett</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mercer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kamata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway</article-title>
<source/>Genes Dev
          <year>2012</year>
<volume>26</volume>
<fpage>1945</fpage>
<lpage>1958</lpage>
<pub-id pub-id-type="doi">10.1101/gad.193458.112</pub-id>
<pub-id pub-id-type="pmid">22892241</pub-id>
</element-citation>
</ref>
<ref id="CR197">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inoue</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Moriya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Miyagawa-Tomita</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Niihori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Oba</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ono</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kure</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ogura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsubara</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome</article-title>
<source/>Hum Mol Genet
          <year>2014</year>
<volume>23</volume>
<fpage>6553</fpage>
<lpage>6566</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu376</pub-id>
<pub-id pub-id-type="pmid">25035421</pub-id>
</element-citation>
</ref>
<ref id="CR198">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gripp</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sol-Church</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Stabley</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Axelrad</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Doyle</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dobyns</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Hudson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tenconi</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phenotypic analysis of individuals with Costello syndrome due to HRAS p.G13C</article-title>
<source/>Am J Med Genet A
          <year>2011</year>
<volume>155a</volume>
<fpage>706</fpage>
<lpage>716</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.33884</pub-id>
<pub-id pub-id-type="pmid">21438134</pub-id>
</element-citation>
</ref>
<ref id="CR199">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kuriyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kawame</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kurosawa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ohashi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ogata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kure</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence and clinical features of Costello syndrome and cardio-facio-cutaneous syndrome in Japan: findings from a nationwide epidemiological survey</article-title>
<source/>Am J Med Genet A
          <year>2012</year>
<volume>158a</volume>
<fpage>1083</fpage>
<lpage>1094</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.35292</pub-id>
<pub-id pub-id-type="pmid">22495831</pub-id>
</element-citation>
</ref>
<ref id="CR200">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costello</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>A new syndrome: mental subnormality and nasal papillomata</article-title>
<source/>Aust Paediatr J
          <year>1977</year>
<volume>13</volume>
<fpage>114</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="pmid">907573</pub-id>
</element-citation>
</ref>
<ref id="CR201">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gripp</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Stabley</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Nicholson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>CI</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Doyle</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Matsubara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zackai</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Lapunzina</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation</article-title>
<source/>Am J Med Genet A
          <year>2006</year>
<volume>140</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.31047</pub-id>
<pub-id pub-id-type="pmid">16329078</pub-id>
</element-citation>
</ref>
<ref id="CR202">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibbs</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Sigal</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Poe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scolnick</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1984</year>
<volume>81</volume>
<fpage>5704</fpage>
<lpage>5708</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.81.18.5704</pub-id>
<pub-id pub-id-type="pmid">6148751</pub-id>
</element-citation>
</ref>
<ref id="CR203">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertola</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Pereira</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Brasil</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Albano</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Krieger</surname>
<given-names>JE</given-names>
</name>
</person-group>
<article-title>Further evidence of genetic heterogeneity in Costello syndrome: involvement of the KRAS gene</article-title>
<source/>J Hum Genet
          <year>2007</year>
<volume>52</volume>
<fpage>521</fpage>
<lpage>526</lpage>
<pub-id pub-id-type="doi">10.1007/s10038-007-0146-1</pub-id>
<pub-id pub-id-type="pmid">17468812</pub-id>
</element-citation>
</ref>
<ref id="CR204">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gripp</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations</article-title>
<source/>Genet Med
          <year>2012</year>
<volume>14</volume>
<fpage>285</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="doi">10.1038/gim.0b013e31822dd91f</pub-id>
<pub-id pub-id-type="pmid">22261753</pub-id>
</element-citation>
</ref>
<ref id="CR205">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Colan</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Noonan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baffa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sol-Church</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Limongelli</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome</article-title>
<source/>Am J Med Genet A
          <year>2011</year>
<volume>155a</volume>
<fpage>486</fpage>
<lpage>507</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.33857</pub-id>
<pub-id pub-id-type="pmid">21344638</pub-id>
</element-citation>
</ref>
<ref id="CR206">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krencik</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hokanson</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Narayan</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Dvornik</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rooney</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Rowitch</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Ullian</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Dysregulation of astrocyte extracellular signaling in Costello syndrome</article-title>
<source/>Sci Transl Med
          <year>2015</year>
<volume>7</volume>
<fpage>286ra66</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aaa5645</pub-id>
<pub-id pub-id-type="pmid">25947161</pub-id>
</element-citation>
</ref>
<ref id="CR207">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rooney</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Goodwin</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Depeille</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sharir</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schofield</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Roose</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>OD</given-names>
</name>
<name>
<surname>Rauen</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>LA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human iPS Cell-Derived Neurons Uncover the Impact of Increased Ras Signaling in Costello Syndrome</article-title>
<source/>J Neurosci
          <year>2016</year>
<volume>36</volume>
<fpage>142</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1547-15.2016</pub-id>
<pub-id pub-id-type="pmid">26740656</pub-id>
</element-citation>
</ref>
<ref id="CR208">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gripp</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Doyle</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dobyns</surname>
<given-names>WB</given-names>
</name>
</person-group>
<article-title>High incidence of progressive postnatal cerebellar enlargement in Costello syndrome: brain overgrowth associated with HRAS mutations as the likely cause of structural brain and spinal cord abnormalities</article-title>
<source/>Am J Med Genet A
          <year>2010</year>
<volume>152a</volume>
<fpage>1161</fpage>
<lpage>1168</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.33391</pub-id>
<pub-id pub-id-type="pmid">20425820</pub-id>
</element-citation>
</ref>
<ref id="CR209">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuhmacher</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sauzeau</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Canamero</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bustelo</surname>
<given-names>XR</given-names>
</name>
<name>
<surname>Barbacid</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition</article-title>
<source/>J Clin Invest
          <year>2008</year>
<volume>118</volume>
<fpage>2169</fpage>
<lpage>2179</lpage>
<pub-id pub-id-type="pmid">18483625</pub-id>
</element-citation>
</ref>
<ref id="CR210">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Viosca</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schuhmacher</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Barco</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Germline expression of H-Ras(G12V) causes neurological deficits associated to Costello syndrome</article-title>
<source/>Genes Brain Behav
          <year>2009</year>
<volume>8</volume>
<fpage>60</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1111/j.1601-183X.2008.00443.x</pub-id>
<pub-id pub-id-type="pmid">18823404</pub-id>
</element-citation>
</ref>
<ref id="CR211">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paquin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hordo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>FD</given-names>
</name>
</person-group>
<article-title>Costello syndrome H-Ras alleles regulate cortical development</article-title>
<source/>Dev Biol
          <year>2009</year>
<volume>330</volume>
<fpage>440</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="doi">10.1016/j.ydbio.2009.04.010</pub-id>
<pub-id pub-id-type="pmid">19371735</pub-id>
</element-citation>
</ref>
<ref id="CR212">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daston</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Ratner</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development</article-title>
<source/>Dev Dyn
          <year>1992</year>
<volume>195</volume>
<fpage>216</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="doi">10.1002/aja.1001950307</pub-id>
<pub-id pub-id-type="pmid">1301085</pub-id>
</element-citation>
</ref>
<ref id="CR213">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krab</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>de Goede-Bolder</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aarsen</surname>
<given-names>FK</given-names>
</name>
<name>
<surname>Pluijm</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Bouman</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>van der Geest</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Lequin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Catsman</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Arts</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Kushner</surname>
<given-names>SA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial</article-title>
<source/>Jama.
          <year>2008</year>
<volume>300</volume>
<fpage>287</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="doi">10.1001/jama.300.3.287</pub-id>
<pub-id pub-id-type="pmid">18632543</pub-id>
</element-citation>
</ref>
<ref id="CR214">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Vaart</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Plasschaert</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rietman</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Renard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oostenbrink</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vogels</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Wit</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Descheemaeker</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Vergouwe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Catsman-Berrevoets</surname>
<given-names>CE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial</article-title>
<source/>Lancet Neurol
          <year>2013</year>
<volume>12</volume>
<fpage>1076</fpage>
<lpage>1083</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(13)70227-8</pub-id>
<pub-id pub-id-type="pmid">24090588</pub-id>
</element-citation>
</ref>
<ref id="CR215">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Payne</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Barton</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ullrich</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Cantor</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hearps</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Cutter</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rosser</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Gioia</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Wolters</surname>
<given-names>PL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1</article-title>
<source/>Neurology.
          <year>2016</year>
<volume>87</volume>
<fpage>2575</fpage>
<lpage>2584</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000003435</pub-id>
<pub-id pub-id-type="pmid">27956565</pub-id>
</element-citation>
</ref>
<ref id="CR216">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stivaros</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tziraki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Mellor</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Jim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Szumanska-Ryt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Parkes</surname>
<given-names>LM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA)</article-title>
<source/>Molecular autism
          <year>2018</year>
<volume>9</volume>
<fpage>12</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-018-0190-z</pub-id>
<pub-id pub-id-type="pmid">29484149</pub-id>
</element-citation>
</ref>
<ref id="CR217">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Omrani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van der Vaart</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mientjes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>van Woerden</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Hojjati</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Levelt</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Smit</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1</article-title>
<source/>Mol Psychiatry
          <year>2015</year>
<volume>20</volume>
<fpage>1311</fpage>
<lpage>1321</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2015.48</pub-id>
<pub-id pub-id-type="pmid">25917366</pub-id>
</element-citation>
</ref>
<ref id="CR218">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howe</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Golshani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Klann</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lipton</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Mucke</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>The mouse as a model for neuropsychiatric drug development</article-title>
<source/>Curr Biol
          <year>2018</year>
<volume>28</volume>
<fpage>R909</fpage>
<lpage>RR14</lpage>
<pub-id pub-id-type="doi">10.1016/j.cub.2018.07.046</pub-id>
<pub-id pub-id-type="pmid">30205056</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>